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ABSTRACT

Thoracic malignancies are one of the deadliest of all cancers, being the leading
cause of cancer death in the Western world. Thoracic malignancies arise from different
tissues; however the most common are of epithelial (commonly referred to as non-small
cell lung cancer, or NSCLC), neuroendocrine (small cell lung cancer, or SCLC) and
mesothelial origin (malignant mesothelioma, or MM). The DNA oncogenic virus Simian
Virus 40 (SV40) has been shown to cooperate with environmental oncogenic fibers in the
onset of MM (Bocchetta et al., 2000, Kroczynska et al., 2006). Insulin like growth factor1 (IGF-1) signaling plays a central role in all thoracic malignancies and in the process of
SV40-mediated malignant transformation of human cells. We have found that in SV40transformed human mesothelial cells (HM) the Large T antigen (Tag), p53, pRb and p300
function in a multi-protein complex to promote transcription of the IGF1 gene. Depletion
of p53 in these cells causes growth arrest because of lack of IGF-1 synthesis. These
results provide a novel mechanistic and biological interpretation of the p53/Tag
complexes and of DNA tumor virus transformation in general. It was generally believed
that one of the major functions of Tag was to bind and inactivate the tumor suppressor
p53. Our data, instead, support a model in which the Tag/p53 complexes are not inert, but
rather play an active, essential role in the process of SV40-mediated transformation of
HM, hence in the pathogenesis of MM.
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Aside from the well-established role played by the IGF-1/Akt-1 axis in thoracic
malignancies, we focused our research on the role of Notch signaling in cancers of the
thorax. Notch-1 signaling has been shown to be required for the growth of SV40transformed human mesothelial cells (Bocchetta et al., 2003). We therefore expanded the
studies of the role of Notch signaling in MM and NSCLC. We have found that, under
hypoxia, the condition that best recapitulates solid tumors microenvironment, both MM
and NSCLC cells have an elevated Notch signaling pathway as compared to normal
human mesothelial (HM) and lung bronchioalveolar cells. Genetic and chemical
modulation of the Notch pathway indicated that these tumor cells are dependent on Notch
signaling. More specifically, MM and NSCLC cell survival was Notch-1 dependent.
Notch-1 through its negative regulation of phosphatase and tensin homolog (PTEN) and
positive regulation of the IGF-1 receptor (IGF-1R) expression causes activation of the
pro-survival IGF-1/Akt-1 signaling pathway. These results provide new insight into the
role of Notch in MM and lung cancer, and strongly implicate that Notch pathway
inhibitors may be useful in the treatment of those deadly diseases. Our data indicate that
targeting Notch-1 signaling using !-secretase inhibitors (GSI) may represent a novel,
promising therapeutic approach for thoracic malignancies treatment, by specifically
targeting hypoxic tumor microenvironment. This is especially important because hypoxic
tumor microenvironment is responsible for poor response to standard anticancer
treatment, tumor recurrence and ultimately death. These results also identify additional
molecular targets that may snergize with Notch-1 inhibition.
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CHAPTER 1
INTRODUCTION

Since its discovery in 1960 as a contaminant of polio vaccines, SV40 has been the
object of extensive studies to assess whether this DNA virus plays a role in human
carcinogenesis. Although this issue has met a broad skepticism in the past two decades,
an increasing amount of data has accumulated linking SV40 to specific types of human
cancer, especially malignant mesothelioma (MM).
Primary human mesothelial cells (HM), as compared to other cells (e.g.
fibroblasts), are uniquely susceptible to SV40 infection/transformation. HM are able to
survive SV40 infection since viral replication takes place at the low rate, which renders
them subjected to the transforming activities of the SV40 oncogenes for a prolonged
time. This translates into a uniquely high rate of SV40 mediated transformation in these
cells (Bocchetta et al., 2000). HM transformation by SV40 is enhanced by environmental
agents, with asbestos being a known etiological agent for MM (Cicala et al., 1993;
Kroczynska et al., 2006).
SV40 major oncogene, large T antigen (Tag), besides its role in an initiation of
viral replication (Wobbe et al., 1985) and regulation of SV40 transcription (Tjian, 1981),
also interacts with host cellular proteins. Among those, interaction with heat shock
protein 70 (HSP70; Sullivan et al., 2000), pRb protein family members (DeCaprio et al.,
!
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1988) and cellular p53 (Pinhasi-Kimhi et al., 1986) appears to be the most intimately
linked to SV40 promotion of cell cycle progression and cell transformation. Tag transactivates a number of genes, which protein products promote cell cycle progression, of
which regulation of insulin like growth factor 1 (IGF-1) signaling appears to be required
for SV40 mediated transformation of human mesothelial cells (HM; Porcu et al., 1992).
SV40 is not able to transform mouse embryonic fibroblasts (MEF) in the absence of
insulin like growth factor-1 receptor (IGF-1R; Sell et al., 1993). The IGF-1R docking
protein insulin receptor substrate-1 (IRS-1; White, 1998) was found in complex with Tag,
which resulted in protection from apoptosis (Zhou-Li et al., 1997). In Aim 1 (results
presented in Chapter 3) we hypothesize that there is a direct transcriptional
regulation of the IGF1 by Tag. Specifically, we tested the involvement of Tag in
regulation of the transcription of the IGF1 in SV40 transformed HM. We sought to
determine whether Tag mediated transactivation of IGF1 requires p53, and if so whether
Tag/p53 complexes can associate with the IGF1 promoter. We also wanted to
characterize the composition of the transactivator complex and determine its location in
the promoter region.
During the process of HM cell transformation, SV40 transcriptionaly up-regulates
Notch-1 signaling (Bocchetta et al., 2003). Interfering with Notch-1 signaling causes
growth arrest of SV40-transformed HM (Bocchetta et al., 2003). Increasing number of
reports suggest pro-oncogenic role of Notch in many solid tumors, however the role of
Notch signaling in MM is not characterized. The family of Notch receptors includes four
isoforms, all of which can play a different role in the malignant setting. It is imperative to
!
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understand what is the role of all Notch isoforms in pathogenesis of MM. Our objective
in Aim 2 (presented in Chapter 4) is to determine what is the outcome of Notch
signaling in MM in general (e.g., irrespective of SV40). Notch signaling can play a
pleiotropic role, and affect signaling of other important pro-survival pathways during
malignant transformation. We hypothesized that given the importance of IGF-1R
signaling in malignant transformation of HM by SV40, Notch can affect the IGF-1/Akt-1
signaling pathway promoting the pro-survival events. Since Notch signaling is dose, time
and context dependent, in our studies we take into consideration all of these variables.
Notch signaling has been studied more in thoracic malignancies of different
histological derivation as compared to MM. In lung cancer there are reports suggesting
that Notch signaling plays a role in non-small cell lung cancer (NSCLC). Our previous
work provided evidence of the oncogenic role of Notch-1 in adenocarcinoma of the lung
(ACL; Chen et al., 2007), the most frequently occurring type of lung cancer. Targeting
Notch using !-secretase inhibitor (GSI) caused ACL cell death under hypoxia, the
condition of low oxygen concentration, which characterizes majority of solid tumor mass.
In Aim 3 (presented in Chapter 5) we try to understand which molecular pathways
are affected by Notch-1 signaling in ACL. Given our previous findings that the primary
isoform that mediates ACL pro-survival effects is Notch-1 (Chen et al., 2007), we
focused on mechanisms that mediate Notch-1 signaling. In T-cell acute lymphoblastic
leukemia (T-ALL) Notch-1 affects Akt-1 signaling by repressing phosphatase and tensin
homolog expression (PTEN; Palomero et al., 2007). Based on our gene expression
studies, we hypothesized that Notch-1 can affect Akt-1 signaling pathway in ACL. In our
!
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studies we wanted to validate whether expression of PTEN, the major inhibitor of Akt-1
signaling, was affected by Notch-1. Given the evidence that hypoxia can enhance Notch1 transcriptional regulation (Gustafsson et al., 2005, Chen et al., 2007), and that hypoxia
was shown to regulate IGF1 expression (Joung et al., 2007), we also looked if Notch-1
can affect other components of the IGF-1/Akt-1 pathway.
Understanding the molecular pathways that underlie malignant transformation of
the two thoracic malignancies of different cell origin (epithelial versus mesothelial)
would provide a better understanding of these malignancies, the role played by Notch
signaling in tumors of different histological derivation, and possibly suggest novel
treatment strategies. If indeed Notch and IGF-1/Akt-1 pathways are interconnected,
targeting Notch signaling pathway using GSI or monoclonal antibodies may represent a
novel and attractive treatment approach for MM and lung cancer patients. Also,
elucidating the mechanisms that are affected by Notch signaling may reveal new
therapeutic targets for the treatment of those deadly malignancies.
In conclusion, our studies have unveiled a molecular circuitry, which involves
SV40/Notch/PTEN/IGF-1 signaling that leads to MM cell survival and malignant growth.
Surprisingly, a similar molecular network takes place in NSCLC leading to similar
physiological outcomes. We can summarize those relationships in the following figure:

!
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Figure 1. Dissertation outline
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CHAPTER 2
REVIEW OF THE RELATED LITERATURE

2.1. THORACIC MALIGNANCIES
Thoracic malignancies are among the most prevalent and the most rapidly
expanding in incidence worldwide. Lung cancer is the most common cause of cancerrelated death in both men and women in the United States and it originates from different
regions in the epithelial component of the airways. Malignant mesothelioma (MM) is
relatively rare, but it is a very aggressive tumor of the cells that form the lining of the
chest, heart and abdomen. Both malignancies differ in the incidence rate, however both
are very aggressive and respond poorly to chemotherapy. Understanding the molecular
mechanisms that underlie the pathogenesis of those deadly malignancies, as well as
finding novel therapeutic strategies appears to be imperative.

2.2. MOLECULAR PATHOGENESIS OF MALIGNANT MESOTHELIOMA
MM is an aggressive tumor of the serosal lining of pleural (lungs and internal chest wall),
pericardial (heart) and peritoneal (abdomen) cavities. MM is among the tumors with the
shortest median survival after diagnosis, with little benefit provided by current
chemotherapies (Carbone et al., 2002). MM arises after malignant transformation of
human mesothelial cells (HM), and its pathogenicity has been traditionally linked to
!"
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environmental fibers exposure (asbestos and erionite; Gazdar et al., 2002). The
mechanisms through which asbestos promotes cellular transformation are unclear, and
may potentially involve: generation of reactive oxygen species (ROS) caused by asbestos
exposure (Heintz et al., 1993); asbestos induced auto-phosphorylation of epidermal
growth factor receptor (EGFR; Robledo and Mossman, 1999) or asbestos mediated
immunosuppressive effects (Rosenthal et al., 1999). More recently, the DNA oncogenic
virus SV40 has been linked to MM (Gazdar et al., 2002). SV40 oncogenic Tag was found
to be expressed in some mesothelioma specimens in complex with p53 (Carbone et al.,
1997) and pRb protein family members (DeLuca et al., 1997). Expression of Tag in HM
without cell lysis can lead to cellular transformation by mechanisms that involve
inactivation of tumor suppressors, activation of pro-survival pathways including IGF1/IGF-1R (Porcu et al., 1994) and other mechanisms. SV40 appears to be required for
MM cell growth and survival. Targeting Tag using antisense technologies in SV40positive MM cell lines caused cell growth inhibition and apoptosis (Weheed et al., 1999).
Other evidences suggest an active role for SV40 in MM pathogenesis. SV40-positive
MM display a characteristic inactivation of the tumor suppressor gene RASSF1A
achieved through methylation of its promoter. Accordingly, progressive methylation of
the RASSF1A promoter is one of the events promoted during the process of SV40mediated HM transformation (Toyooka et al., 2002). Furthermore, SV40 cooperates with
asbestos in inducing MM in vitro and in vivo (Bocchetta et al., 2000; Kroczynska et al.,
2006) and exacerbates DNA damage caused by asbestos (Pietruska and Kane, 2007). The
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presence of a MM epidemic in parts of Turkey suggests that genetic predisposition may
also play a major role in MM onset (Carbone et al., 2007, Dogan et al., 2006).

2.3. MOLECULAR PATHOGENESIS OF LUNG CANCER
Lung cancer develops from normal bronchoepithelial cells through a multistep
process that involves successive genetic and epigenetic changes that lead to inactivation
of tumor suppressor genes, and/or activation of proto-oncogenes, and is usually
associated with cigarette smoking (Sato et al., 2007).
Some of the most important abnormalities in growth-stimulatory signaling
pathways, which activate proto-oncogenes, work through deregulation of receptor
tyrosine kinase (RTK) activity. Among those, over-expression of EGFR is found in the
majority of NSCLC (Bunn and Franklin, 2002) and similarly another member of the
ErbB RTKs HER2/neu is highly expressed in 30% of NSCLCs (Bunn et al., 2001). MYC
phosphoprotein is amplified in 18-31% small cell lung cancers (SCLCs) and 8-20% in
NSCLCs (Richardson and Johnson, 1993). Most oncogenic mutations in lung cancer are
KRAS mutations (Sato et al., 2007), with RAS activating mutations found in 10-15% of
NSCLCs, especially in ACL (Sekido et al., 2003). The catalytic subunit of
Phosphatidylinositol 3-kinase (PI3K) is mutated in 3% of NSCLCs, and results in
elevated kinase levels (Samuels et al., 2004).
Signal Transducers and Activators of Transcription (STAT) family members
STAT3 and STAT5 contribute to lung cancer by stimulating proliferation and inhibiting
apoptosis through activation of transcription of the relevant genes (Karamouzis et al.,
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2007). NSCLCs with mutated EGFR show enrichment of STAT3 activation, which
mediate oncogenic effects of mutant EGFR (Alvarez et al., 2006).
Other important mechanisms that lead to lung cancer pathogenesis involve
inactivation of major tumor suppressor genes including p53 and pRb. The transcription
factor p53 is a protein that is stabilized in response to multiple stimuli including hypoxia,
DNA damage and oncogenic stress. Activation of p53 leads to the expression of genes
that are involved in cell cycle arrest or apoptosis (P21, BAX, PUMA etc.; Vousden and
Lu, 2002). P53 is inactivated by mutation in 90% of SCLCs and 50% of NSCLC
(Takahashi et al., 1989). Most inactivating mutations of P53 are point mutations (adducts
at p53 critical residues) and to a lesser extent homozygous deletions, and are frequently
caused by tobacco smoke carcinogens (benzo[a]pyrene; Hainaut et al., 1998). MDM2 is
an important p53 regulator involved in its degradation by polyubiquitination and is
amplified in 6% of NSCLCs, resulting in loss of p53 function (Higashiyama et al., 1997).
p14ARF, which is another relevant p53 regulator, is lost in 65% of SCLCs and 40% of
NSCLCs and is associated with the loss of p53 expression and activation (Gazzeri et al.,
1998; Vonlanthen et al., 1998). Mutations in the gene coding for p14ARF may result in
deregulated expression of p16INK4A which is derived from the same locus.
Majority of lung cancers carry the mutation in one of the components of p16INK4A
– cyclin D1 - CDK4 – pRb cell cycle regulatory pathway, which in turn causes abnormal
functioning of its other components. In effect, majority of SCLCs have inactivated tumor
suppressor gene pRb (found in almost 90% of SCLCs and only in 15-30% of NSCLCs;
Reissmann et al., 1993) whereas p16INK4a, a protein that regulates pRb function and
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keeps it in the tumor suppressor state, is frequently inactivated in NSCLCs (70%;
Belinsky et al., 1998). Decreased activation of p16INK4a is due to homozygous deletion,
mutation or promoter hypermethylation. pRb pathway can also be inactivated by
overexpression of CDK4 (amplified in a subset of NSCLCs) or Cyclin D1 (overexpressed
in 40% NSCLCs) by blocking the growth suppressive activity of p16INK4a (Sherr and
McCormick, 2002).

2.4. NOTCH SIGNALING
Notch is an evolutionary conserved family of single transmembrane receptors that
participate in the development of multicellular organisms by regulating the following
critical processes: lateral inhibition, lineage specification and boundary formation
(Radtke and Raj, 2003). To date, four Notch receptor paralogs (Notch 1-4) and five
Notch ligands have been identified in mammals (Delta-like-1, Delta-like-3, Delta-like-4,
Jagged-1 and Jagged-2; Lai 2004). Notch is synthesized as a single precursor protein, and
during post-transcriptional processing in trans-Golgi becomes cleaved by furin-like
proteases into heterodimer comprising of an extracellular domain (NEC) non-covalently
associated with transmembrane domain (NTM; Fig. 2; Miele, 2006). NEC contains multiple
EGF-like repeats, whereas NTM consists of extracellular ‘Lin-Notch’ repeats, a singlepass transmembrane domain and an intracellular domain, the latter composed of
‘RAM23’ (which participates in CBF-1/RBPJ! binding, see below), six ankyrin repeats
and a polyglutamine stretch and a PEST region, possibly involved in ubiquitination
(Nickoloff et al., 2003). Upon ligand binding NEC dissociates from NTM, and becomes
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endocytosed along with the ligand by ligand expressing, neighboring cells. This event
activates cleavage of extracellular fragment of NTM catalyzed by ADAM10 or ADAM17
metalloproteases, followed by intracellular cleavage mediated by !-secretase (aspartyl
protease; Brou et al., 2000). This second cleavage releases the intracellular fragment
(NIC), which is able to translocate into the nucleus, where it binds CBF-1 and regulates
transcription of its target genes (Miele, 2006). The mammalian member of CBF1Suppressor of Hairless-Lag1 (CSL) transcription factors CBF-1 binds to a consensus
sequence cGtGGGAA and acts as a transcriptional repressor by binding to a corepressor
complex that includes SMRT or N-coR, SKIP, CIR, HDAC, SHARP, CtBP and CtIP
(Miele, 2006). NIC binding to the CBF-1-corepressor complex replaces SMRT and
histone deacetylase (HDAC) for transcriptional coactivators including mastermind like-1
(MAML1) and histone acetyl transferases (HAT) and results in activation of target genes
(Lai, 2004). The number of genes that are directly or indirectly regulated by Notch is
large and depends on the cellular context. The most common are the bHLH (basic helixloop-helix) transcription factors families: HEY, HES (hairy/enhancer of split in
Drosophila melanogaster) and HERP. Other Notch target genes include p21Cip/Waf,
CyclinD1, CyclinA, transcription factors of the NF"B family, poly (ADP-ribose)
polymerase and SKP2 ubiquitin ligase which triggers degradation of p27Kip1 (Sarmento et
al., 2005). Some of the Notch transcriptional targets have been shown to be also MYC
targets in primary human T-cell lymphoblastic leukemia and include genes that regulate
cell growth (Palomero et al., 2006); in the same system cMYC itself is a direct target of
Notch (Weng et al., 2006).
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Notch signaling is involved in many developmental events that are highly

context-dependent. Notch activation determines cell fate by controlling responsiveness to
either proliferative or differentiation stimuli, and allows for their proper interpretation.
Depending on the conditions Notch can have differential effects on cell’s
proliferation and apoptosis. Notch-1 promotes differentiation of keratinocytes (Nickoloff
et al., 2002) and myeloid progenitor cells (Schroeder and Just, 2000). On the other hand,
induction of Notch stimulates proliferation of mammary epithelial cells (Lee et al., 1999)
and hematopoietic progenitor cells (Carlesso et al., 1999).

2.5. NOTCH AND CANCER
The oncogenic role of Notch was first identified in T-ALL (Reynolds et al., 1987)
and is associated with chromosomal translocation resulting in deregulated expression of
truncated form of Notch-1, which corresponds to NIC (Radtke and Raj, 2003). Other
studies showed that activating mutations of Notch-1 that stabilize NIC or facilitate the
cleavage of it are found in almost 80% of T-ALL (Mansour et al., 2007). There is an
increasing evidence that aberrant Notch signaling plays a role in many cancers.
Deregulated expression of Notch pathway components was demonstrated in other cancers
of hematopoietic origin, like B-cell chronic lymphoid leukemia (B-CLL; Hubmann et al.,
2002), as well as in Hodgkin's and large cell anaplastic lymphomas (Jundt et al., 2002).
Altered expression of Notch receptors and ligands was demonstrated in many solid
tumors. Truncated, constitutively active Notch-1 and Notch-4 cause mammary tumors in
mice (Callahan and Raafat, 2001; Dievart et al., 1999; Gallahan and Callahan, 1997) and
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high expression of Notch-1 and Jagged-1 has been associated with poor prognosis in
breast cancer (Reedijk et al., 2005). Overexpression of intact Notch receptors has been
documented in cervical, pancreatic, endometrial, renal, lung, colon, head and neck
carcinomas (Zagouras et al., 1995; Miele et al., 2006) and melanoma (Balint et al., 2005).
A large line of evidence supports the role of Notch in contributing to tumor
progression. However in certain types of cancer Notch has been shown to have a tumor
suppressor function. Notch-1 induces growth arrest and promotes differentiation of
keratinocytes in humans and mice (Nickoloff et al., 2002; Rangarajan et al., 2001).
Overexpression of NIC inhibits proliferation of myeloid progenitor cells (Schroeder and
Just, 2000). In B cells apoptosis caused by NIC expression is mediated through HES
family of proteins, whereas growth arrest is mediated independently (Morimura et al.,
2000). Activated Notch-1 expression induces cell cycle arrest in SCLC by up-regulating
cyclin-dependent kinase inhibitors WAF1 (p21) and KIP1 (Sriuranpong et al., 2001).
However, since the effects of Notch signaling are strictly dose- and time-dependent,
experiments with over-expressed active form of Notch could lead to artifacts and should
be interpreted bearing this caviat in mind. Our results in ACL cell lines reveal that the
effects of Notch signaling depend on oxygen concentration (Chen et al., 2007). We found
that in normoxic environment Notch-1 suppresses growth, whereas under low oxygen
concentration Notch-1 promotes survival of ACL cells. Thus, when studying biological
functions of Notch signaling in cancer, many variables need to be considered including
dose, time and environment.
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2.6. NOTCH IN MALIGNANT MESOTHELIOMA
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Increasing number of reports indicate oncogenic role of Notch in solid tumors.
The role of Notch signaling in MM is poorly understood. Notch-1 expression is elevated
in MM biopsies as compared to stromal tissue. Notch-1 is required for the maintenance of
Simian Virus 40 (SV40) transformed phenotype of HM, and inhibition of Notch-1
resulted in SV40-transformed HM cell growth arrest (Bocchetta et al. 2003). Expression
of Notch-1 in those cells is regulated primarily by small tumor antigen (tag), which
inactivates protein phosphatase 2A (PP2A; Testa and Giordano, 2001), resulting in an
increased phosphorylation of the components of the ERK pathway. There are no reports
indicating the role of Notch signaling in MM that is independent of SV40.

2.7. NOTCH IN LUNG CANCER
Over-expression of Notch-1IC caused growth arrest of SCLC cell lines
(Sriuranpong et al., 2001). Hence, this study suggested a tumor suppressive role in SCLC.
Three studies proposed an oncogenic role for Notch-3 in NSCLC. Dang et al. (2000)
found a chromosomal translocation t(15;19) in an aggressive lung carcinoma. Similar
translocations were found in two separate thoracic malignancies case reports (Kees et al.,
1991; Lee et al., 1993) including a thymic carcinoma (Kubonishi et al., 1991). The likely
gene to be affected by such translocation was proposed to be Notch-3 because the
NSCLC cell line HCC2429 (harboring such translocation) expressed high levels of the
Notch-3 mRNA (Dang et al., 2000). Moreover, 7 out of 44 NSCLC cell lines expressed
the Notch-3 mRNA as determined by Northern blot hybridization (Dang et al., 2000).
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The Dang group further expanded on these early findings. The expression of a
truncated Notch-3 receptor (missing the intracellular portion of the protein, and therefore
considered as a Notch-3 dominant negative form) caused reduced growth of NSCLC cells
and increased “growth factor dependence” (Haruki et al., 2005). In a more recent study,
treatment of NSCLC cell lines with a GSI (MRK-003) reduced tumor formation in
xenografts mouse models. When Notch-3 was genetically inhibited through RNA
interference, the same cells became GSI insensitive, indicating that Notch-3 was the
target of the GSI used (Konishi et al., 2007). These results, and their interpretation, are
somewhat controversial. In Haruki et al. (2005) the authors have not explored the
possibility that the truncated, dominant negative Notch-3 over-expressed in their NSCLC
cells could have saturated the cell membrane with a non-functional Notch receptor,
ultimately resulting in the expression of a Notch pan-inhibitor. This possibility is
reinforced by the fact that the authors did not verify that in their experimental conditions
activation of Notch-1, -2 and -4 was still attainable. The study of Konishi et al. (2007) is
also difficult to interpret. The authors propose an oncogenic role for Notch-3 in NSCLC.
However, when Notch-3 was down-regulated genetically, NSCLC cells grew and formed
tumors. If Notch-3 was the main oncogene in NSCLC cells, Notch-3 siRNA should have
yielded similar effects as dominant negative Notch-3 and chemical inhibition. Therefore
it does not seem to be the case that the role of Notch-3 in NSCLC is yet well understood.
A recent study (Zheng et al., 2007) showed that forced expression of constitutively active
Notch-1 inhibited growth of the ACL line A549 cultured in standard conditions and
interfered with tumor growth in vivo. We obtained analogous results in the same cell line
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cultured in normoxia (Chen et al., 2007). However, experiments generated from
Notch-1 over-expression are difficult to interpret and may lead to artifactual results.
Dissimilar conclusions drawn by Zheng et al. (2007) were proposed by a Chinese study
based on immunohistochemical analysis of NSCLC tumor biopsies compared to normal
“bronchi mucosa” (Jiang et al., 2007). These authors observed strong Notch-1
immunoreactivity in NSCLC compared to normal lung, which correlated with Jagged-1
and VEGF expression. The intensity of the immunostaining appeared to increase with
more advanced tumor stages. This was not observed in the study by Chen et al. (2007)
performed on snap-frozen tissue samples. In conclusion, a better understanding of the
role played by Notch receptors in lung cancer still awaits further study.

2.8. NOTCH AND HYPOXIA
Due to the high cell expansion and insufficient neo-vascularization, solid tumors,
including MM and lung cancer, are highly hypoxic. Rapid proliferation of tumor cells
requires increased glucose metabolism. The lack of oxygen shifts glucose metabolism
from oxidative phosphorylation to anaerobic glycolysis, which results in accumulation of
pyruvate and lactate. Tumor cells adapt to the hypoxic microenvironment by inducing the
expression of genes that promote cell survival, motility and angiogenesis (Keith and
Simon, 2007). Hypoxia Inducible Factor-1" (HIF-1") is the major transcription factor
responsible for regulation of expression of genes under hypoxia. Genes that are directly
regulated by HIF-1" include: Erythropoetin (EPO), Vascular Endothelial Growth Factor
(VEGF), and Inducible Nitric Oxide Synthase (iNOS; Gordan and Simon, 2007). Under

!
18!
normoxic conditions HIF-1" becomes degraded by ubiquitin mediated proteasomal
pathway. Under hypoxia HIF-1" is stabilized and can promote tumor progression. In B
progenitor cells forced expression of Notch leads to acute lymphoblastic leukemia (Pear
and Aster, 2004). In many cell types, including neuronal progenitors, hypoxia relies on
Notch to maintain the undifferentiated state. Hypoxia promotes Notch-1 stabilization and
induces transcription of Notch responsive genes by recruiting HIF-1" to the target gene
promoters (Gustafsson et al., 2005). These findings suggest that oxygen concentration is
an important determinant of Notch function, and needs to be accounted for in studying
Notch signaling pathways in MM and lung cancer.

2.9. IGF-1R PATHWAY
The insulin like growth factor-1 (IGF-1) signaling pathway is a complex system
involved in regulation of processes that lead to cell growth, proliferation and
development. Uncontrolled transduction of signals through IGF-1R may result in
pathological conditions including transformation, metastasis and evasion of apoptosis.
The IGF-1R system is composed of IGF-1 ligands (IGF-1, IGF-2), transmembrane
receptors (IGF-1R, IGF-2R and insulin receptor-IR) composed of " and # subunits, and
IGF binding proteins (IGFBPs) which affect bioavailability of IGFs in extracellular fluids
(LeRoith and Roberts, 2003). Upon ligand binding to the extracellular domain of the
receptor, conformational change of the receptors occurs, which leads to the autophosphorylation of the receptor’s tyrosine residues on the # subunit. This, through
docking molecules such as members of the insulin receptor substrate (IRS) family (IRS-
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1, IRS-2, IRS-3, IRS-4) and or Src homology 2 domain containing transforming
protein (SHC), results in activation of either PI3K or mitogen activated protein kinase
(MAPK) pathways. PI3K is a major downstream effector of RTKs. It is a lipid kinase,
and catalyzes the phosphorylation of PIP2 to form phosphatidylinositol-3,4,5triphosphate (PIP3). PIP3 is a second messenger at the plasma membrane where it
recruits Akt-1 (serine-threonine protein kinase, protein kinase B; Cantley, 2002). This
event ultimately leads to activation of downstream effectors, and expression of target
genes that mediate the proliferative and anti-apoptotic effects of IGF-1 induced Akt-1
signaling (LeRoith et al., 1995). The major supressor of the Akt-1 pathway is a lipid
phosphatase PTEN, which dephosphorylates PIP3 to PIP2 at the plasma membrane to
prevent the recruitment of Akt-1, and progression of the proliferative signal.

CHAPTER 3
THE SV40 LARGE T ANTIGEN REGULATES IGF-1 EXPRESSION IN
TRANSFORMED MESOTHELIAL CELLS

ABSTRACT
During SV40 mediated malignant transformation of human mesothelial cells
(HM), oncogenic viral antigen Tag promotes cell proliferation by interfering with prosurvival and tumor suppressive pathways. Tag is found in complex with p53, and the
current view is that those complexes are the way to sequester and inactivate cellular p53.
On the other front, Tag promotes cell survival by inducing insulin like growth factor-1
(IGF-1) signaling which leads to cell proliferation. Using primary human cells and SV40transformed human cells, we show that in addition to inactivating p53 tumor suppressor
activities, the Tag-p53 complex has growth stimulatory activities that are required for
malignant cell growth. We found that in human cells, Tag/p53 complexes regulate
transcription of the IGF1 gene by binding to the IGF1 promoter together with pRb and
p300. Depletion of p53 leads to structural rearrangement of this multi-protein complex,
resulting in IGF1 promoter transcriptional repression and growth arrest. Our data provide
a novel mechanistic and biological interpretation of the p53/Tags complexes and of DNA
tumor virus transformation in general. In the model we propose, p53 is not a passive
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inactive partner of Tag. Instead thep53/Tag complex promotes malignant cell growth
through its ability to activate the IGF-1 signaling pathway.

INTRODUCTION
IGF-1 pathway plays a critical role in regulating normal cell growth and
transformation events. IGF1R-/- mice are less than half the size of normal counterparts at
birth and are viable for only a few hours (Liu et al., 1993). Mice lacking insulin receptor
substrate-1 (IRS-1) are severely growth impaired, although being viable and reaching
fertility (Araki et al., 1994; Tamemoto et al., 1994).
In malignant setting IGF-1R is frequently over-expressed, and it functions as a
potent anti-apoptotic agent supporting cell survival of neuronal, hematopoietic and
fibroblast cells, to the point that IGF-1R signaling is commonly referred to as “cell
survival factor” (Gluckman et al., 1992; Rodriguez-Tarduchy et al., 1992; Harrington et
al., 1994). IGF-1R is absolutely required for the successful transformation of a number of
cell lines (reviewed in Baserga, 1995). Furthermore, fibroblasts obtained from IGF1R-/mice are virtually resistant to cell transformation operated by a variety of chemical
carcinogens, as well as viral and cellular oncogenes (Sell et al., 1994). SV40 mediated
cell proliferation requires the interaction of IGF-1 with its receptor (Porcu et al., 1992).
Intact IGF-1R is required for SV40 mediated transformation of primary HM (Sell et al.,
1993). Tag can promote cell cycle progression in BALB/c 3T3 cells cultured in low
serum only when IGF-1/IGF-1R pathway is active (Valentinis et al., 1994).
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During malignant transformation DNA viral oncoproteins can bind and

inactivate p53 tumor suppressor functions (Tag of human polyomaviruses JCV, BKV and
SV40, the E1b of adenoviruses; Ali and DeCaprio, 2001). This allows infected cells to
survive, and prevent p53-mediated apoptosis or cell growth arrest. Inactivation of p53
impairs DNA repair thus favoring the early steps of carcinogenesis. The latter effect is
mediated mostly by the ability of p53 to induce p21 expression, a CDK inhibitor that in
turn causes cell cycle arrest, allowing DNA repair to take place. By inducing p21
expression, p53 prevents cells that have accumulated genetic damage from undergoing
mitosis and propagating the damaged DNA to the progeny. Due to its critical role in
regulating the cell cycle, and DNA damage, which results in proper cell growth, cancer
cells need to find ways to inactivate wild-type p53. Accordingly, inactivation of p53 must
occur to transform primary cells in vitro (Hahn et al., 1999). Oncogenic viruses other
than SV40 have developed unique mechanisms for inactivating p53; HPV16 oncoprotein
E6, binds to cellular p53 promoting its ubiquitylation and degradation (Wernes et al.,
1990; Scheffner et al., 1990).
The current hypothesis is that, upon Tag binding, p53 loses its ability to work as a
transcription factor and as a tumor suppressor gene (Bargonetti et al., 1992; Jiang et al.,
1993; Segawa et al., 1993). A few studies have shown, however, that Tag in complex
with p53 does not prevent p53 from binding to its DNA binding sites (Long et al., 1995;
Sheppard et al., 1999; Technau et al., 2001). Moreover, p53 complexed with Tag was
able to stimulate transcription of a p53-regulated promoter in cell free extracts from
monkey and human cells (Sheppard et al., 1999). SV40-mediated transformation of
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fibroblasts was enhanced by wild type mouse p53 (Michalovitz et al., 1986). Similarly,
transformation of rat fibroblasts required both Tag and stabilized p53 (Deppert et al.,
1989). Animal studies have shown that SV40 is more efficient in promoting tumor
growth in the presence of wild type p53 (Herzig et al., 1999). These data did not fit with
the generally accepted view that the major role of DNA viral Tags is to bind to and
inhibit cellular p53.
Primary HM have high levels of p53, and in such environment SV40 requires
IGF-1R signaling for cellular transformation. Here we investigated the possible
biological effects of Tag-p53 complexes on IGF-1/IGF-1R pathway mediated cell growth
and transformation.
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MATERIALS AND METHODS
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CELLS AND GENE TRANSFER PROCEDURES
Primary human mesothelial cell (HM) cultures were obtained from non-cancerous
donors, cultured and characterized as described in Bocchetta et al. 2000. These cells
contain wild-type p53 (Bocchetta et al., 2000). SV40-transformed HMs (S-HML) were
obtained through HM infection with SV40 virions (10 plaque forming units –pfu/cell).
Six to eight weeks after infection tridimensional foci of transformed cells were hand
picked and cultured into cell lines. The latter were grown in DMEM supplemented with
5% fetal bovine serum (FBS). Critical results were confirmed in three independent SHMLs.
Retroviral packaging was performed with Phoenix cells using standard
procedures. S-HML transduced with the retrovirus expressing the tetracycline regulator
(TR; TET-ON system, Clontech Laboratories Inc., Mountain View, CA) were selected
using 600 µg/ml of G418. After selection, the functionality of the system was assayed as
recommended by the manufacturer. These cells were transduced with the retrovirus
expressing HPV16 E6 (in the presence of doxycycline). Transduced cells were then
selected with 600µg/ml of hygromycin and the resulting clone was named S-HML/E6.
Western blot and immunostaining experiments were performed as described in
Bocchetta et al. 2000.
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DNA SYNTHESIS ANALYSES
Detection of proliferating cells by the measurement of the DNA replication was
performed using the 5-bromo-2'-deoxyuridine (BrdU) Flow kit (BD PharMingen,
Franklin lakes, NJ) according to the manufacturer’s instructions. Briefly, 1 x 106 cells
were stimulated with IGF-1 (5 nM) in culture medium. A total of 100 $l of BrdU solution
(1 mM BrdU in PBS) was added to each dish containing 10 ml culture medium and was
incubated for 8 hours at 37°C. The cells were then fixed and permeabilized with
Cytofix/Cytoperm buffer (BD PharMingen). To prevent cells form clumping (which
would interfere with FACS analysis) the cellular DNA was digested with DNAse for 1 h
at 37°C. The cells were stained with an anti-BrdU FITC-conjugated antibody and
analyzed by FACSCanto Flow Cytometer (BD Bioscience, San Jose, CA). Cells that
stained positively for BrdU indicated actively proliferating ones.
Apoptosis was assayed using Annexin V/7-aminoactinomycin D staining
according to standard procedures.

RNA STUDIES
Nuclear run-on assays were performed as described in Bocchetta et al. 2003. Each
slot of alkali-denatured probes contained 5 µg of probe DNA, which corresponded to: a
133 bp PCR fragment of the human 18S rRNA gene; a 654 bp PCR fragment of the
human p21 cDNA; a 378 bp PCR fragment of the human Bax cDNA; a 593 bp PCR
fragment of the human IGF1 cDNA; # phage DNA digested with Hind III. After
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hybridization to P-labelled nuclear transcripts, membranes were washed and exposed
to both X-ray film and a phosphoimager.
RT-Real time PCR was performed using standard protocols. Briefly, cells were
dissociated with trypsin/EDTA, harvested, and snap frozen. Total cellular mRNA was
obtained using the RNeasy kit (Qiagen, Valencia, CA) in the presence of RNAse-free
DNAse I. The concentration of RNA in each sample was measured using
spectrophotometer (GE Healthcare, Uppsala, Sweden), and the quality of the mRNA was
assayed in 1% formaldehyde agarose gels. Two µg of total RNA from each sample was
reverse transcribed using a first strand synthesis kit (MBI-Fermentas, Hanover, MD) in
the presence of 10 pmol of random primers. Real Time PCR was performed as follows:
1/5 of the reverse transcription reaction from each sample was diluted serially in H2O to
determine the optimal range of dilution for the samples (CT between 15 and 25), using a
Gene Amp 5700 (PE-Applied Biosystems, Wellesley, MA). Oligo pair combinations (see
Table 2) were chosen using the Primer Express 1.0 software (Applied Biosystems).
Reactions were performed using the SYBR GREEN PCR Master Mix (Applied
Biosystems). After estimating the sample with higher levels of GAPDH mRNA, 1:2 serial
dilutions were made in H2O (range 1 to 128) to construct a calibration curve for each
mRNA. Similar calibration curves were run along with each experiment. “No reverse
transcription” of each sample was run as the negative control. mRNA values were
normalized for GAPDH amounts, and plotted as a percentage of the control sample.
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Reporter assays were performed using the Dual-Glow Luciferase Assay system

(Promega, San Luis Obispo, CA) and measured with a luminometer (Veritas; Turner
Biosystems, Sunnyvale, CA).

CHROMATIN IMMUNOPRECIPITATION ASSAYS
Crosslinking of 1 x 107 cells was performed for 10 mins at a room temperature
using 1% formaldehyde in PBS. The reaction was stopped, by adding 0.25 M glycine in
PBS. The cells were harvested and the DNA was sheared by sonication in lysis buffer (20
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40) supplemented with 1% SDS, using a
Branson SONIFIER 250 (Wolf Laboratories Lmd, UK) to generate DNA fragments $600
bp. Cell lysates were diluted ten times with lysis buffer to reduce the SDS final
concentration to 0.1%. Lysates were precleared with protein A/G agarose beads (Pierce,
Rockford, IL) for 4 hr at 4°C, and were then incubated overnight at 4°C with the
respective primary antibodies. Immune complexes were collected on Protein A/G agarose
beads overnight at 4°C. Samples were dialyzed twice against dialysis buffer (2 mM
EDTA pH 8.0, 50 mM Tris-HCl pH 8.0). Following 4 washes in 1 ml wash buffer (100
mM Tris-HCl pH 8.0, 500 mM LiCl, 1% NP-40); immune complexes were eluted from
the beads by vigorously shaking twice for 15 minutes in 150 µl of 50mM NaHCO3, 1%
SDS. Cross-linking was reversed by incubation in 0.15 M NaCl overnight at 65°C. Each
sample’s DNA was ethanol precipitated and purified using QIAprep spin miniprep kit
(Qiagen). DNA was resuspended in 100 µl of TE buffer. Finally, each sample was PCR
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amplified using appropriate oligonucleotides as primers (Table 2), and the results were
visualized on 2% agarose gels.

ANTIBODIES
Target

Type

Company

HPV16 E6 Ab-1

mouse monoclonal

EMD Bioscience

anti Xpress

mouse monoclonal

Invitrogen

IGF-1R 2C8

mouse monoclonal Santa Cruz Biotech

IGF-1 H-70

rabbit polyclonal

Santa Cruz Biotech

p300 H-272

rabbit polyclonal

Santa Cruz Biotech

p300 D-12

mouse monoclonal Santa Cruz Biotech

Tag pAb419

mouse monoclonal Santa Cruz Biotech

p53 DO-1

mouse monoclonal Santa Cruz Biotech

pRb IF-8

mouse monoclonal Santa Cruz Biotech

mdm2 D-12

mouse monoclonal Santa Cruz Biotech

P21 187

mouse monoclonal Santa Cruz Biotech

GAPDH MAB374 mouse monoclonal

Chemicon

Table 1. A list of all antibodies used in Chapter 3

Annexin V PE-conjugated was from BD Biosciences (Franklin Lakes, NJ).
Agarose-conjugated protein A/G was from Pierce (Rockford, IL).
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HPV16 E6 was PCR amplified from pE6E7 (Dr Martin W. Kast, University of
Southern California, CA) and ligated into different plasmids. The constructs used here
were the following: pE6CDNA4, in which E6 was cloned into the Kpn I/Not I sites of
pcDNA4/HisMax (Invitrogen); pREVE6, in which the recombinant E6 obtained after the
construction of pE6cDNA4 was PCR amplified and cloned into the Hind III/Cla I sites of
pREV-TRE (Clontech Laboratories, Mountain View, CA). In retroviral transduction
experiments the Tet-On Gene Expression System (Clontech) was used. It included pTetON, encoding the tetracycline transactivator, pTRE-d2EGFP, used to validate the
functionality of the TET-ON clones, and pREV-TRE, which expresses proteins under the
control of a CMV minimal promoter that contains four tetracycline responsive elements.
All vectors can be used as ordinary plasmids, or they can be packaged in retroviral
particles. pSmaBgl-LUC was provided by Dr Renato Baserga (Kimmel Cancer Center,
PA). pMDM2 was provided by Dr Zhuo Zhang (University of Alabama, AL). pGRI5,
expressing wild type human IGF1R under the control of a CMV promoter was a gift from
Dr Clodia Osipo (Loyola University Chicago, IL). p53mt135, expressing dominant
negative

p53

was

purchased

from

BD

Biosciences.

Oligonucleotides

5’GATCCCGCAATGGTTCACTGAAGACCCAGGTCCAGAGAAGCTTTCTGGACC
TGGGTCTTCAGTGAACCATTGTTTTT-3’and 5’CTAGAAAAACAATGGTTCACT
GAAGACCCAGGTCCAGAAAGCTTCTCTGGACCTGGGTCTTCAGTGAACCATT
GCGG-3’ were annealed in 20 mM Tris-HCl pH 7.4, 1 mM EDTA pH 8.0, 100 mM
NaCl by incubating 2 nmoles of each primer at 100°C for 5’. The reaction was then left
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to slowly cool down to room temperature in a heat block. Annealing was verified by
running the products before and after annealing onto a 10%, non-denaturing
polyacrylamide gel. The annealed products were ligated into the Bam HI and Xba I sites
of pGE-1 (Gene Eraser, Stratagene, La Jolla, CA) to give rise to plasmid shp53.

Gene

Primer Sequence

P21-A

5’-CCTGCCGAAGTCAGTTCCTTG- 3’

P21-B

5’- GCGGCAGACCAGCATGACAG -3’

P21-C

5’- AAACTGAGACTAAGGCAGAAGATGTAGAGC -3’

Bax-A

5’- ATGGACGGGTCCGGGGAGC -3’

Bax-B

5’- GCAGAGGATGATTGCCGCCG -3’

Bax-C

5’- GCACAGGGCCTTGAGCACCA -3’

GAPDH-F

5’- CAATGACCCCTTCATTGACC -3’

GAPDH-R

5’- TTGATTTTGGAGGGATCTCG -3’

IGF-1 A

5’- CTTCTGTTTGCTAAATCTCACTGTC -3’

IGF-1 B

5’- TTTTATTTCAACAAGCCCACAGGG -3’

IGF-1 C

5’-GGGCTGATACTTCTGGGTCTTGG-3’

MDM2-F

5’- GATCCTGGAAGTGTCCCTGA-3’

MDM2-R

5’- AAGGACCGTTCTGTTTGTGG-3’

18S F

5’-TGATTAAGTCCCTGCCCTTTGT-3’

18S R

5’-TCAAGTTCGACCGTCTTCTCAG-3’

Table 2. A list of oligonucleotides used in Chapter 3
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p21: Primers A and C were used to amplify a 654 bp fragment used as probe in nuclear
run-on experiments, while primers B and C were used in RT-Real time experiments
(positions 504-654 of the p21 cDNA).
Bax: Primers A and C were used to amplify a 378 bp fragment used as probe in nuclear
run-on experiments, while primers B and C were used in RT-Real time experiments
(positions 228-378 of the Bax cDNA).
IGF-1: Primers A and C were used to amplify a 593 bp fragment used as the probe in
nuclear run-on experiments, while primers B and C were used in RT-Real time
experiments (positions 393-593 of the IGF1 cDNA).
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Region

Primer sequence

Position

A-F

5’- GGTACCCCAAAGCCTCTCATG-3’

-1952 to -1700

A-R

5’- CCCAACTACAACATCCCTAGG-3’

-1952 to -1700

B-F

5’-GCCCCTGAAGGGACTTGACC-3’

-1764 to -1414

B-R

5’-GACTCTCAGGGGACTGACAC-3’

-1764 to -1414

C-F

5’-CCAGAGTAGGATTTCAAGCAG-3’

-1472 to -1078

C-R

5’-CTGGCTAGCAATACCCTCTTG-3’

-1472 to -1078

D-F

5’-AGAACCGTGAATTCTCAATGGC-3’

-1215 to -921

D-R

5’-GCAAACAATTTTCCTGTTGTTTG-3’

-1215 to -921

E-F

5’-CTGGCACACAGACTCCCTCTG-3’

-1031 to -659

E-R

5’-GGAAGACAGCACTCGGGTGAC-3’

-1031 to -659

F-F

5’-ACCAATCCAATGCTGCCTGCC-3’

-757 to -464

F-R

5’-TTTCTGCTGGGCATGAAGACAC-3’

-757 to -464

G-F

5’-TAGAATCTAAAATTGCTCTC-3’

-555 to -322

G-R

5’-AAATAACATCATACCTTTGC-3’

-555 to -322

cont-F

5’-CAGTCTTCTGTGTCCTGTTC-3’

N/A

cont-R

5’-AGAGGCTGATGGGAAGGAAC-3’

N/A

Table 3. A list of oligonucleotides used for ChIP experiments on the
IGF-1 promoter
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IGF1 was artificially downregulated using Hs_IGF1_5_HP Validated siRNA (Qiagen).
The negative control for ChIP assays was a 266 bp region (part of BAC RP11-25I15,
locus AC089982, a sequence far from known genes located on chromosome 12q12, while
the IGF1 gene is located on chromosome 12q22).

RESULTS

S-HML/E6 CELLS EXPRESS FUNCTIONALLY ACTIVE RECOMBINANT HPV16 E6
S-HM are characterized by high levels of endogenous p53. We wanted to study
the effects of lowering p53 in cells expressing the SV40 Tag. To achieve this goal, we
expressed HPV16 E6, an oncoprotein which binds and targets p53 for ubiquitin mediated
degradation (Wernes et al., 1990; Scheffner et al., 1990) in S-HML. We used a stable,
tetracycline inducible transduced cell clone expressing a fusion protein consisting of 6
histidines at its N-terminal portion (for conjugation to Ni-charged carriers), an Xpress
peptide flag and the full length HPV16 E6. These cells (named S-HML/E6) express the
SV40 Tag and upon doxycycline treatment also expressed HPV16 E6 that bound and
degraded p53 (Fig. 3 and Fig. 4).
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Figure 3. E6 induction down-regulates p53 and p53 regulated gene products. (A)
Expression of Tag and p53 in S-HML expressing E6 (which degrades p53, Fig.4). (B)
Reduced p53 expression is paralleled by decreased p21 and mdm2 expression. Cells were
treated with or without doxycycline for 48 hr to induce E6 expression. E6: S-HML/E6
cells. CONT: control cells. (C) Transient transfection of S-HML with pE6CDNA4 causes
marked p53 downregulation. C24: control 24 hr after transfection; E624: E6 24 hr after
transfection; C48: control 48 hr after transfection; E648: E6 48 hr after transfection.
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We measured p53 and Tag expression levels at different time-points after
doxycycline induction in S-HML/E6 cells. 48 hr after doxycycline-mediated induction of
HPV16 E6, S-HML/E6 had reduced protein expression of p53, and is followed by the
reduction in expression of its targets p21 and mdm2 (Gudkov and Komarova, 2003). Tag
expression was not influenced by doxycycline treatment (Fig. 3A, B). We hypothesized
that these effects could have caused apoptosis/mitotic catastrophe, or a proliferative
advantage. Instead, Annexin V/ propidium iodide (PI) staining followed by FACS
analysis did not show evidence of apoptosis or the appearance of aberrant DNA peaks (an
indication of mitotic catastrophe), and S-HML/E6 showed a doxycycline, dose-dependent
reduction in DNA synthesis as compared to controls (Fig. 4A). Since doxycycline has
pleiotropic effects that might have influenced these findings, we expressed recombinant
E6 protein in transiently transfected S-HML. We obtained identical results: E6transfected S-HML had undetectable p53, and were growth arrested as compared to
controls (Fig. 3C and Fig. 4B). The reciprocal experiments (growth curves for the
inducible system and DNA incorporation assay for S-HML transiently transfected with
E6) gave identical results (Bocchetta et al., 2008). To understand why depletion of
cellular p53 in S-HML resulted in growth arrest, we investigated genes that are
transactivated by Tag (Chen et al., 1996, Porcu et al., 1994). We found no variation in
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cdc2 protein expression after doxycycline treatment of S-HM/E6, while the same
treatment virtually abolished IGF-1 precursor and IGF-1R expression (Fig. 4C).

Figure 4. E6 induction in S-HML suppresses DNA synthesis and causes cell growth
arrest. Critical components of the IGF-1 signaling pathway are downregulated upon
either E6 or mdm2 induction. (A) Bromodeoxyuridine (BrdU) incorporation assay
conducted on control cells (squares) and SV40 transformed human mesothelial cells
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transfected with plasmid expressing E6 (S-HML/E6; bullets) performed at increasing
doxycycline concentrations. The histogram is the average of 4 independent experiments;
each measurement was determined on 30,000 events. The percentages of DNA
incorporation of ES-HML/E6 versus control cells were (at concentrations of doxycycline
in µg/ml): 0, 62.78 ± 24.40%; 0.1, 55.00 ± 16.67%; 0.4, 37.22 ± 11.11%; 1.0, 22.44 ±
13.33%. The apparent lowered DNA incorporation measured in S-HML/E6 versus
control cells at 0 µg/ml of doxycycline may be explained by “leaky” transcription at the
“tet-on” retroviral promoter. (B) Cell growth curves of S-HML transfected with a control
plasmid (pcDNA4/His-Max; squares) and with the same plasmid expressing recombinant
E6 (bullets). The histogram is the average of three independent experiments. Using a
plasmid expressing green fluorescent protein followed by FACS analysis we determined
that the efficiency of transfection was > 95% (using electroporation). (C) Western blot
analysis performed in S-HML/E6 and control cells in the presence and absence of
doxycycline. Representative experiment. Western blot was performed 48 hr after
antibiotic exposure (+ lanes). E6: S-HML/E6. (D; Top) Western blot analysis performed
on HM transfected with the control plasmid (“cont” lane) or with the plasmid expressing
recombinant E6 (“E6” lane). (D; Bottom) Western blot analysis conducted on S-HML
transfected with a control plasmid (“cont” lanes) and with a plasmid expressing human
mdm2 (mdm2 lanes). Note mdm2 expression and downregulation of p53, p21, IGF-1 and
IGF-1R.

The effects observed upon E6-transfection appeared to be dependent on the presence of
Tag, because E6-transfection of primary HM (which do not contain SV40) caused the
opposite effect: a 4.3 fold increase of IGF-1 expression (Fig. 4D; Top). Since E6 did not
influence Tag expression but influenced p53 expression in S-HML (Fig. 3A) we
speculated that the E6 activities in Tag containing cells were mediated through the
degradation of p53. To test our hypothesis that the decreased expression of p21, mdm2,
IGF-1 and IGF-1R upon E6 induction was related to p53 down-regulation, we
deregulated p53 in S-HML using a shRNA against p53, a dominant negative p53
(p53mt135, which interferes with proper p53 complex formation; Fig 5A and 5B,
respectively) or over-expressing mdm2 in S-HML (Fig. 4D; Bottom): all these
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approaches yielded reproducible p21, IGF-1 and IGF-1R down-regulation. The most
effective and reproducible way to down-regulate p53 expression in S-HML was
expressing HPV16 E6 in these cells (Fig. 3C). Combined together, these results
suggested that the decreased expression of p21, IGF-1 and IGF-1R was related to p53
depletion independently of how it was achieved.

Figure 5. Both p53 down-regulation through RNAi and transfection of S-HML with
dominant negative p53 cause reduced expression of p21, mdm2, IGF-1 and IGF-1R.
(A) Western blot analysis of the indicated gene products after transfection of S-HML
with the plasmid encoding shp53. (B) Western blot analysis of the indicated gene
products after transfection of S-HML with the plasmid encoding dominant negative p53.
!
E6-MEDIATED P53 DOWN-REGULATION CAUSES S-HML CELL GROWTH ARREST THROUGH
THE IGF-1/IGF-1R SIGNALING PATHWAY

To confirm that p53 depletion in S-HML causes cell growth arrest through IGF1/IGF-1R signaling, we designed the experiment summarized in Fig. 6A.
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Figure 6. E6-mediated inhibition of DNA synthesis in S-HML is mediated through
the IGF-1/IGF-1R pathway. 1%, cells grown in 1% FBS; IGF-1, cells grown in 1%
FBS plus IGF-1. (A) Schematic of the experiment performed to verify the hypothesis that
E6-mediated impairment of DNA synthesis in S-HML is exerted through the IGF-1
signaling pathway. (B) BrdU/FACS analysis performed on 1Cc cells grown in 1% FBS
containing medium (red graph) or grown in medium supplemented with 1% FBS and 5
nM IGF-1 (blue graph). Note that IGF-1 can resume DNA synthesis in these cells. (C)
Same as in (B) performed on 1C6 cells. Note that these cells are unable to respond to
IGF-1 stimulation. (D) Same as in (B) performed on 1R6 cells. Note that forced
expression of the IGF-1R resumes the ability of S-HML to respond to IGF-1 stimulation.
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S-HML were transfected with a plasmid expressing the IGF-1R under the control of a
CMV promoter (1R cells). S-HML transfected with the empty plasmid served as control
(1C cells). Both 1R and 1C cells were transfected in parallel with either the E6 expressing
plasmid (yielding either 1R6 or 1C6 cells) or with the control plasmid for E6 (yielding
either 1Rc or 1Cc cells). 24 hr after transient transfection cells were cultured in 1% FBS,
or in 1% FBS supplemented with 5nM of purified IGF-1. 48 hr after transient transfection
all cells were analyzed for DNA synthesis using BrdU incorporation assay/FACS
analyses (Fig. 6 B-D). Both 1Rc and 1Cc (these cells do not express E6 and have normal
p53 amounts) were able to resume DNA synthesis after IGF-1 treatment (Fig. 6B).
Instead, 1C6 cells (which have down-regulated p53 and the IGF-1R is under the control
of its own promoter) could not resume DNA synthesis (Fig. 6C). However, 1R6 cells
(which have down-regulated p53 but an IGF-1R under the control of a CMV promoter;
Fig. 7C) resumed DNA synthesis upon IGF-1 stimulation (Fig. 6D).
These data confirmed that E6-mediated down-regulation of p53 in S-HML
impaired DNA synthesis, and support the notion that the growth impairment was
mediated through the effects of the Tag-p53 complexes on the IGF-1 signaling pathway.
This interpretation was supported by the finding that E6 expression in HMs that do not
contain Tag did not affect the rate of DNA synthesis in these cells (Bocchetta et al.,
2008).
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Figure 7. IGF-1R expression in S-HML and in 1R cells. (A) Mouse preimmune IgG.
(B) IGF-1R expression in S-HML. (C) IGF-1R expression in 1R cells. Nuclei were
counterstained with hematoxylin. Original magnification 400 X.
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We hypothesized that the decreased expression of p21, mdm2 and IGF-1 protein
levels detected after E6-mediated p53 depletion in S-HML (SV40 transformed HM cells)
could have been mediated at the transcriptional level. Treatment of S-HML with IGF-1
caused increased expression of the IGF-1R, while a siRNA directed against IGF1 caused
decreased IGF-1R expression in S-HML (Fig. 8). Therefore, we concluded that the study
of the IGF-1 promoter regulation would have provided major insights into the positive
IGF-1/IGF-1R autocrine feed-back loop in S-HML.

Fig. 8. IGF-1 regulates IGF-1R expression levels in S-HML. (A) S-HML were
transfected either with a control siRNA (cont.) or with a validated siRNA targeting the
IGF1 mRNA (RNAi; 1 nmole/106 cells). After transfection, cells were cultured in
DMEM supplemented with 5% FBS. 48 hr after transfection cells were harvested and
assayed by Western blot analysis. Results were visualized and quantitated using a
Fujifilm LAS 3000 imaging system. Note that a reduction of about 60% of the IGF-1
precursor was paralleled by about 3-fold reduction of the IGF-1R expression. (B) S-HML
were cultured either in DMEM supplemented with 1% FBS (1% lane), or in DMEM
supplemented with 1% FBS including 5 nM IGF-1 (IGF-1 lane). Note that IGF-1
stimulation caused a 2.4-fold increase in the IGF-1R expression level in S-HML.
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We used real time PCR to study expression of IGF1 and other genes that are

under regulation of p53. We found that E6-mediated p53 down-regulation in S-HML
almost abolished P21 and IGF1 mRNA expression, and caused a 50% and 80% reduction
in the expression of the Bax (a gene also regulated by p53) and MDM2 mRNAs,
respectively (Fig. 9A). Nuclear run-on experiments confirmed that the transcriptional
activity of these promoters is suppressed in S-HML expressing E6 (Fig. 9B). To further
verify that E6 induction in S-HML caused repressed transcription at the IGF1 promoter
we performed reporter assays using a plasmid kindly provided by Dr R. Baserga (Thomas
Jefferson University, Philadelphia, PA), in which firefly luciferase is under the control of
the rat IGF1 promoter (Porcu et al., 1994; see Fig. 10 for the map of this plasmid).
Inhibition of p53 by the induction of E6 in S-HML/E6 caused a 70% reduction of
firefly luciferase activity as compared to controls (Fig. 9C). This suggests that the
presence of p53 along with Tag is required to transactivate IGF1 expression. We
hypothesized that either Tag or p53 (or both) directly binds to the IGF1 promoter and
regulates its transcription. We first tested this hypothesis using the rat IGF1 promoter,
since it was previously characterized (Porcu et al., 1994) and the results supported our
hypothesis (Bocchetta et al., 2008). The results in the rat model suggested that Tag and
cellular p53 can directly or indirectly associate with the IGF1 promoter in S-HML.
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Figure 9. E6 induction in S-HML causes transcriptional repression at p53-regulated
promoters. Tag and p53 bind to the rat IGF-1 promoter in vitro. (A) Steady-state
levels of the Bax, p21, mdm2 and IGF-1 mRNA in S-HML transfected with a control
plasmid (C columns) and with a plasmid expressing recombinant E6 (E6 columns). The
measurements were taken 48 hr after transfection. The histogram represents the average
of 4 independent experiments, each measurement was taken in triplicate over a curve of 6
dilutions of cDNAs. GAPDH mRNA was used as the internal control for each sample.
Setting the control plasmid-transfected S-HML at 100%, the E6 transfected S-HML
displayed the following averages: Bax, 20.59 ± 14.71%; p21, 0.32 ± 0.04%; mdm2, 53.75
± 11.25%; IGF-1, 0.02 ± 0.01%. (B) Left: representative nuclear run-on experiment
performed on nuclei of S-HML transfected either with the control plasmid or the E6expressing plasmid. The experiments were conducted 48 hr after transfection.
Radioactivity associated with each band was measured with a phosphoimager. Right:
average of four independent experiments. Setting the controls at 100%, the E6 transfected
S-HML displayed the following averages: p21, 19.84 ± 12.70%; IGF-1, 23.80 ± 17.46%;
Bax, 26.98 ± 20.63%; 18S, 92.06 ± 12.70%. Error bars represent standard deviation. (C)
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Reporter assay conducted on S-HML/E6 and control cells in the presence and the
absence of doxycycline. Firefly luciferase was under the control of the rat IGF1 promoter
(pSmaBgl-LUC0). Cells were transfected, then cultured in the presence or absence of
antibiotic. 48 hr after culturing, 10 µg of total cell lysates were assayed for the luciferase
activity. The values were measured as firefly luciferase units/renilla luciferase light units.
The histogram is the average of 12 independent experiments. The results were as follows:
control cells cultured in the absence of doxycycline: 97.89 ± 30.53; control cells cultured
in the presence of 2 µg/ml doxycycline: 95.79 ± 34.73; S-HML/E6 cultured in the
absence of doxycycline: 83.16 ± 28.42; S-HML/E6 cultured in the presence of 2 µg/ml
doxycycline: 26.32 ± 16.21. Asterisk: P > 0.01. Courtesy of Maurizio Bocchetta.

Fig. 10. Map of pSmaBgl-LUC plasmid. Plasmid map provided by Dr Renato Baserga
(see also ref. Porcu et al., 1994).
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To test whether Tag and cellular p53 were associated with the IGF1 promoter in
S-HML we resorted to chromatin immunoprecipitation (ChIP) assays. We aligned the
sequence of the rat promoter with the genomic sequence of the human IGF1 region. The
fragment in the human IGF-1 promoter that showed the highest homology with the rat
promoter (72% nucleotide identity) was the one spanning positions -1952 to -322 of the
human IGF1 promoter (+1 is the IGF1 initiation codon). This promoter region was
analyzed by ChIP assay dividing the 1630 bp DNA promoter region in 7 partially
overlapping amplicons (Fig. 11A).

Figure 11. Tag and p53 associate with the IGF1 promoter. (A) Schematic of the
region of the IGF1 promoter that was assayed by ChIP. Tag and p53 associate only with
region A and B. (B) ChIP assay performed on untransfected S-HML. Abbreviations: H20,
reaction performed in the absence of any template; con, immunoprecipitation (IP)
performed using a pre-immune serum as the primary antibody; Tag, IP performed with an
anti-Tag as the primary antibody; p53, IP performed with an anti-p53 as the primary
antibody; p300, IP performed with an anti-p300 as the primary antibody; input, 10% of
the total input DNA. (C) ChIP assay performed on transfected S-HML. Abbreviations: c,
S-HML transfected with a control plasmid; E6, S-HML transfected with the E6
expressing plasmid; con, IP performed using a pre-immune serum as the primary
antibody; input, 10% of the total input DNA. (D) ChIP assays performed using anti pRb
and p300 as the primary antibodies. Abbreviations are the same as in Panel C. The
experiments shown here were repeated three times.
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As a negative control, we used a 266 bp region on chromosome 12q12, a region

distant from any known gene. We compared non-transfected S-HML to p53-depleted SHML via E6 transfection. Cells were cross-linked, then cell lysates were mechanically
sheared and immunoprecipitated with antibodies specific for either Tag (Fig. 11B, lanes
3) or p53 (Fig. 11B, lanes 4). The crosslinking in immunoprecipitated materials was
reversed and PCR-amplified with primers that yielded the amplicons outlined in Fig.
11A. In non-transfected S-HML (cells with an active IGF1 promoter) Tag was associated
with the “B” region, and p53 was associated with both the “A” and “B” regions (Fig.
11B). Instead, in p53-depleted S-HML, p53 was associated only with the “B” region (Fig.
11C, lanes 7 and 8), and Tag was associated prevalently with the “A” region (Fig. 11C,
upper panel, compare lanes 5 and 6), although the signal corresponding to the “B” region
persisted (Fig. 11C, lanes 5 and 6, bottom panel). This indicated that upon E6-mediated
p53 down-regulation the Tag-p53 complex on the IGF1 promoter underwent a
conformational change, with Tag moving upstream (i.e. to the A region) from the IGF1
starting codon and p53 losing occupancy of the same region. To further investigate the
Tag-p53 complex on the IGF1 promoter, we tested the “A” through “G” region of the
IGF1 promoter by ChIP for two major binding partners of Tag: pRb and p300 (reviewed
in Ali and DeCaprio, 2001). When we immunoprecipitated S-HML extracts using a pRbspecific antibody we PCR-amplified region “B” (Fig. 11D, lane 3). When we
immunoprecipitated using a p300-specific antibody we amplified both “A” and “B”
regions (Fig. 11B, lane 8). No other region of the portion of the IGF1 promoter was
amplified. These data indicated that within the 538 bp encompassing the “A” and “B”
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regions of the IGF1 promoter there is a multi-protein complex that includes Tag, p53,
pRb, and p300. When we decreased p53 expression through E6 induction we were still
able to amplify region “B” by immunoprecipitating with the pRb-specific antibody (Fig.
11D, lane 7), however immunoprecipitations conducted with the p300 antibody failed to
yield both the “A” (not shown) and “B” amplicons (Fig. 11D, lane 8). This indicated that
upon p53 depletion, the multi-protein complex at regions -1952 to -1414 of the IGF1
promoter underwent modifications that included structural rearrangements of individual
complex partners and exit of p300, a transcriptional co-activator (Ogryzko et al., 1996).
The result of these modifications was paralleled by transcriptional inhibition at the IGF1
promoter. We detected no quantitative differences in the amount of pRb bound to the “B”
amplicon before and after E6-mediated p53 depletion in S-HML using quantitative PCR
(Bocchetta et al., 2008). No E6 association with the IGF1 promoter was detected.
Furthermore, no association of either Tag or p53 was detected on the IGF1R promoter
using ChIP analysis (not shown).
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Here we present evidence that Tag/p53 complexes bind to the IGF1 promoter,
stimulating IGF1 expression and the IGF-1 signaling pathway, an effect that leads to cell
growth. Specifically, we found that the Tag/p53 complexes interact with the IGF1
promoter as part of a complex that consists of several partners, including pRb and p300.
When we depleted p53 we observed a loss of p300 on the IGF1 promoter. Our results
provide an explanation for a number of studies that had found that the presence of wildtype p53 was required to stimulate transcription in polyomaviruses-mediated malignant
cell transformation (Long et al., 1995; Sheppard et al., 1999; Technau et al., 2001;
Michalovitz et al., 1986; Deppert et al., 1989; Herzig et al., 1999).
One of the current views about p53 is that its transcriptional and biological
activities are impaired by its binding to the Tags of DNA tumor viruses. A similar view
in the DNA tumor virus field assumes that the oncogenes of these viruses bind to and
“inactivate” cellular p53, a process that is required for viral replication and also for virusmediated cellular transformation. Here we present evidence that this vision is incorrect,
because downregulation of p53 caused decreased expression of p53 regulated genes. This
supports the idea that in SV40-transformed HM p53 retains at least some transcriptional
regulation activity. More importantly, Tag/p53 complexes acquire new transcriptional
and biological activity. These findings support recent studies, showing that Tag requires
p53 to interact with p300, and RNAi-mediated p53 depletion disrupted Tag-p300
interactions (Borger and DeCaprio, 2006). Therefore, we propose the following model
(Fig. 12).
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Fig. 12. Model of Tag/p53 regulation of the IGF1 promoter. Top: In S-HML cells,
with active transcription at the IGF1 promoter, a protein complex (which includes Tag,
p53, pRB, p300 and very likely other members) occupies a region spanning positions 1952 to -1414 of the IGF-1 promoter. Bottom: Upon p53 depletion this protein complex
undergoes a number of rearrangements that include spatial redistribution of members of
this complex (e.g., Tag translocates upstream in the promoter), loss of protein
components (e.g., p300 and a fraction of p53). This rearranged complex interferes with
transcription of the IGF1 gene.
In normal S-HML a multiprotein complex that includes Tag, p53, pRb and p300
occupies positions -1952 to -1414 (+1 is transcription start site) of the IGF1 promoter.
Upon p53 depletion (obtained using different techniques) this complex undergoes
structural rearrangements, probably as a result of the exit of some critical components
(such as p300) that ultimately regulate the transcription of the IGF1 gene.
The biological effects observed upon SV40 infection are species specific (Gazdar
et al., 2002) because rodent cells are non-permissive to SV40 replication, whereas human
cells are. Therefore, animal models could not be used to test, in vivo, the possible
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oncogenic effects of the findings reported here. Nonetheless, one study in mice
reported higher SV40-mediated oncogenicity (Tag transgenic mice where Tag was under
a control of insulin promoter in the % pancreatic cells) in wild type mice compared to p53
null mice (Herzig et al., 1999).
In our experimental model we used mesothelial cells and SV40. Specifically, we
used different primary HM obtained from separate donors with non-malignant pleural
effusions (Bocchetta et al., 2000). We used HM because these cells allow SV40
replication and are rarely lysed by the virus, thus HM are ideal to study the biological
interactions among Tag and p53 (Bocchetta et al., 2000). HM are also frequently
transformed by SV40 (Bocchetta et al., 2000; Gazdar et al., 2002), an effect that allowed
us to compare the Tag/p53 biological activities in both primary and malignant human
cells. Given that similar effects were observed in SV40-transformed primary human
astrocytes (brain tumor is the second most common tumor type related to SV40), the
results presented are potentially of general relevance (Bocchetta et al., 2008). It should be
noted that p53 depletion caused decreased IGF1R expression in both S-HML and SV40transformed human astrocytes. Although no direct association of p53 or Tag was detected
on the IGF-1R promoter, Tag/p53 complexes may regulate IGF1R expression indirectly
(Valentinis et al., 1994). Alternatively, the expression of IGF1R may be mainly under the
control of a positive feed-back loop regulated by autocrine IGF-1.
In summary, our data provide evidence that SV40 directly manipulates the IGF1/IGF-1R signaling pathways to promote HM malignant transformation. This situation
implicates the dysregulation of IGF-1 signaling as a putative early pathogenic event in
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the onset of MM. We propose that exacerbated IGF-1R signaling (and downstream
Akt-1 activation) may allow fiber-damaged cells’ survival, an event that would favor
further genetic damage that may ultimately lead to MM progression.

CHAPTER 4
THE ROLE OF NOTCH SIGNALING IN MALIGNANT
MESOTHELIOMA

ABSTRACT
Malignant mesothelioma (MM) is a cancer of the lining of the lungs, heart, and
intestine and is known to respond poorly to chemotherapy. Here we show that malignant
mesothelial cells have elevated Notch-1 signaling as compared to normal human
mesothelial cells (HM). We studied the role of Notch in MM under normoxic and
hypoxic conditions, the later condition best recapitulating the MM microenvironment.
Genetic and chemical modulation of the Notch pathway indicated that MM cells are
dependent on Notch signaling. More specifically, this signaling was Notch-1 dependent
as the result of its negative transcriptional regulation on phosphatase and tensin homolog
(PTEN), which led to activation of the pro-survival Akt-1 signaling pathway.
On the contrary, Notch-2 expression is lost in MM. This differential expression of
the two Notch isoforms benefits cancer cell survival as re-expression of Notch-2 was
toxic to MM cells. The mechanism of Notch-2 toxicity to MM cells countered that of
Notch-1 as it was the result of positive transcriptional regulation of PTEN and inhibition
of the Akt-1 signaling pathway. These results provide new insight into the role of Notch
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in MM and suggest that Notch pathway inhibitors may be useful in the treatment of
this deadly disease.

INTRODUCTION
MM is among tumors with the shortest median survival after diagnosis, with little
benefit provided by current chemotherapies (Carbone et al., 2002). MM has been linked
to environmental fibers exposure (asbestos and erionite; Gazdar et al., 2002), SV40
infection (Gazdar et al., 2002, Kroczynska et al., 2006), however genetic predisposition
may also play a role in MM (Carbone et al., 2007, Dogan et al., 2006). Mesothelioma is
generally treated with surgical resection followed by adjuvant chemotherapy (Burgin et
al., 2009). Non-resectable MM cases are treated with a combination of pemetrexed (a
folate antimetabolite) and cisplatin (Burgin et al., 2009). However, the median survival
after diagnosis is still a dismal 12.7 months. It is therefore essential to obtain a better
understanding of the molecular mechanisms that underlie MM and to identify novel
therapeutic strategies for the treatment of this disease.
Our previous work in adenocarcinoma of the lung (ACL) reveals that when
studying molecular pathways in solid tumors, one needs to take into account the
oxygenation status of the tumor tissue (Chen et al., 2007). In this regard, it should be
underscored that MM is a severely hypoxic malignancy (Klabatsa et al., 2006). Hypoxic
microenvironment seems to profoundly affect signaling through Notch receptors
(especially Notch-1). Hypoxia inducible factor-1& (HIF-1&) has been shown to stabilize
Notch-1IC and to greatly increase Notch-1/CBF-1-mediated transcriptional activity in
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myogenic and neuronal stem cells (Gustafsson et al., 2005). We have confirmed these
effects in ACL cells, where we showed that in hypoxic conditions Notch-1 provides
essential survival signals to ACL (Chen et al., 2007).
Notch signaling has been increasingly linked to cancer, although the biological
effects of Notch activity appear to be tissue-specific. Activated Notch signaling was
confirmed in T-cell acute lymphoblastic leukemia (T-ALL; Weng et al., 2004), breast
(Reedijk et al., 2005) and prostate cancer (Santagata et al., 2004). Notch-1 is a tumor
suppressor in mouse and human skin (Nicolas et al., 2003; Thelu et al., 2002). Ectopic
expression of Notch-1IC led to growth arrest of SCLC (Sriuranpong et al., 2001). In
certain tumor types the role played by specific Notch receptors is still debated.
In a previous study, we showed that Notch-1 activation was required during the
process of SV40 mediated transformation of primary human mesothelial cells (HM)
(Bocchetta et al., 2003). Inhibition of Notch-1 activation led to growth arrest of SV40transformed HM (Bocchetta et al., 2003). In this chapter we analyze the role of Notch
signaling in MM in general (e.g., irrespective of SV40). Given that the effects of Notch
signaling are dose-, time- and context-dependent (Lewis, 1998), we plan to study Notch
signaling taking all those variables into account. Specifically, tumor microenvironment
appears to play a role in mediating crucial molecular events, especially hypoxia and
Notch signaling (Gustafsson et al., 2005; Chen et al., 2007). Since MM is among the
most hypoxic solid tumors, we analyze the role of Notch in MM in hypoxic conditions.
Based on the results presented in Chapter 3, and the evidence that insulin-like
growth factor-1 (IGF-1) signaling is important for HM transformation and the
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maintenance of the transformed phenotype, in this section we want to determine
whether Notch interacts with the IGF-1/Akt-1 pro-survival pathway. Our findings
indicate that Notch-1 and Notch-2 play opposite roles in MM cell survival. Expression of
Notch-1 leads to the down-regulation of PTEN, Akt-1 activation, increased DNA
synthesis and MM cells survival, while Notch-2 induction leads to PTEN activation, Akt1 dephosporylation and MM cell death.
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CELL CULTURE, HYPOXIA, GAMMA-SECRETASE INHIBITOR AND RNA STUDIES
Primary human mesothelial cell cultures (HM) were obtained and characterized
from ascites fluids obtained from non-cancerous patients as previously described
(Bocchetta et al., 2000). HM were grown in DMEM supplemented with 10% FBS.
Mesothelioma cell lines (ME) were obtained and characterized from primary tumors as
previously described (Pass et al., 1995). ME were grown in DMEM supplemented with
10% FBS. All cells were fingerprinted using the GenePrint fluorescent STR system
(Promega). Cells grown in hypoxia were maintained in chambers (Stem Cell
Technologies) filled with certified 1% O2, 5% CO2 and 94% N2 (Airgas North Central) at
37 °C. Oxygen concentration was measured with MiniOX1 oxygen meters (Mine Safety
Appliances Company).
The gamma secretase inhibitor (GSI) MRK-003 was dissolved in DMSO to make
40 mM stock solutions.
Laser capture microdissection was performed on 8 µm-thick frozen MM and
normal lung specimens using a Pixcell II Laser capture Microdissection System (Arcturus
Engineering Inc.). Normal human pleura (HP) was captured from normal lung biopsies
after identifying mesothelial cells using the Histogene® LCM Immunofluorescence
Staining Kit (Molecular Devices) with some modifications. Briefly, we used a
biotinylated primary antibody specific for mesothelin, following the manufacturer’s
protocol. Cy3-streptavidin was replaced with HRP-conjugated streptavidin, and color was
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developed in 3’ using the DAB substrate (Vector). Samples were rapidly de-hydrated,
and processed for laser capture microdissection. MM specimens were stained using the
HistoGeneTM LCM frozen section staining kit (Arcturus) and microdissected as described
above. We collected ~500 cells for each sample. RNA was extracted using the
PicoPureTM RNA isolation kit (Arcturus) and amplified using the RiboAmpTM RNA
amplification kit (Arcturus; 1/4 of the original total RNA preparation was used directly
for 18S rRNA normalization). Total RNA was purified from cultured cells using the
RNeasy Mini kit (Qiagen). Reverse transcription and Real Time PCR analysis were
performed as described (Chen et al., 2007). Briefly, quantitative real-time PCR was
performed with SYBR Green PCR Master Mix (Applied Biosystems) in an ABI 7300
thermal cycler (Applied Biosystems). For each sample, a serial dilution of cDNA
template was measured in triplicate. Non-RT reactions served as controls. All
measurements were normalized for 18S rRNA. Comparison between groups were
analyzed by Student’s t-test, with alpha < 0.05.
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Primer Sequence
Notch-1 F

5’-TGTTGTGTGTCATGCCAGTG-3’

Notch-1 R

5’-AACATCTTGGGACGCATCTG-3’

Notch-2 F

5’-GCCTGGCAGTGTTACCTCAT-3’

Notch-2R

5’-GTCCCTGAGCAACCATCTGT-3’

HEY-1 F

5’-TCCTGCCTCCTTCTCTTTGA-3’

HEY-1 R

5’-CCAGTTCAGTGGAGGTCGTT-3’

HES-5 F

5’-GCCCGGGGTTCTATGATATT-3’

HES-5 R

5’-GAGTTCGGCCTTCACAAAAG-3’

PTEN F

5’-ACCAGGACCAGAGGAAACCT-3’

PTEN R

5’-GCTAGCCTCTGGATTTGACG-3’

18S F

5’-TGATTAAGTCCCTGCCCTTTGT-3’

18S R

5’-TCAAGTTCGACCGTCTTCTCAG-3’

Table 4. List of all oligonucleotides used in Chapter 4
Sequences of oligonucleotides used in this chapter are provided in Table 4. A list
of antibodies used in this chapter is reported in Table 5. Notch-1IC and Notch-2IC cloned
into pcDNA3.0 (Invitrogen) have been previously described (Chen et al., 2007). The
same inserts were subcloned into pLenti4/TO/V5-DEST to generate the Notch-1IC-DEST
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and Notch-2 -DEST to obtain doxycyline-inducible expression of either Notch-1 or
Notch-2IC in lentiviral vectors (the backbone system was the ViraPower T-Rex Lentiviral
System; Invitrogen).

ANTIBODIES
Target

Type

Company

Cat. number

Notch-1 (C-20)

Rabbit polyclonal

Santa Cruz Biotech.

SC-6014R

Active Notch-1

Rabbit

Cells Signaling

2421s

Notch-2

Rabbit polyclonal

Abcam

ab8927

Notch-3 (M-134)

Rabbit polyclonal

Santa Cruz Biotech.

SC-5593

Notch-4 (L-16)

Goat polyclonal

Santa Cruz Biotech.

SC5594

Jagged-1

Goat polyclonal

Santa Cruz Biotech.

SC-6011

Delta-1,4

Goat polyclonal

Santa Cruz Biotech.

SC-8155

Hes-1

Mouse monoclonal BD Transduction Lab.

611596

Hes-5

Goat polyclonal

Santa Cruz Biotech.

SC-13859

Hrt-1 (H-120)

Rabbit polyclonal

Santa Cruz Biotech.

SC-28746

Akt

Goat polyclonal

Santa Cruz Biotech.

SC-1618

p-Akt

Rabbit monoclonal

Cells Signaling

4058 S

p-mTOR

Rabbit polyclonal

Cells Signaling

3061S

p-Pdk-1

Rabbit polyclonal

Cells Signaling

2971 S

Pdk-1

Rabbit polyclonal

Cells Signaling

3062
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PTEN

Rabbit polyclonal

Cells Signaling

9552

p21

Mouse monoclonal

Santa Cruz Biotech.

SC-817

GAPDH

Mouse monoclonal

Chemicon

MAB374

p-Jnk

Rabbit polyclonal

Cell Signaling

2676

Bax

Rabbit polyclonal

Santa Cruz Biotech.

SC-493

Bcl-2

Rabbit polyclonal

Santa Cruz Biotech.

SC-8351

IL-7

Rabbit polyclonal

Santa Cruz Biotech.

SC-7921

Mesothelin

Mouse monoclonal

Santa Cruz Biotech.

SC-33672

Pancytokeratin

Mouse monoclonal

Zymed

18-0132

Carcinoembryonic
Mouse monoclonal
Antigen

Zymed

18-0057

Zymed

18-0291

Calretinin

Mouse monoclonal

Table 5. List of all antibodies used in Chapter 4

A short hairpin targeting Notch-1 (shNotch-1) was obtained by annealing
complementary DNA oligonuclotides (Chen et al., 2007); the resulting double-stranded
DNA was ultimately cloned in pLenti4/TO/V5-DEST to obtain a tetracycline-inducible
lentiviral system conditionally expressing shNotch-1.
We generated 4 tetracycline-inducible ME stably expressing the genes of interest
under the control of the TR (tetracycline regulator) as follows. First, cells were
transduced with the TR lentivirus and selected with blastycidin (3 µg/ml); then they were
transduced either with Notch-1IC, Notch-2IC, or shNotch-1, and selected with zeocin (200
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µg/ml) according to the manufacturer’s instructions. Cells transduced with the empty
pLenti4/TO/V5-DEST lentiviral vectors (abbreviated pDest in most Figures) were used
as the controls. In different set of experiments, we artificially downregulated Notch-1 and
Notch-2 expression using commercially available siRNAs (Santa Cruz Biotechnologies).
The non-specific siRNA (negative control) was commercially available (Santa Cruz
Biotechnologies). Constitutively active Akt-1 (N-terminal myristoylatable Akt-1) cloned
into the pUSEamp(+) expression plasmid (abbreviated as “pUSE” in Figures) was
purchased from Upstate (Millipore). Transient transfections were performed using an
electroporator (Gene Pulser II, Biorad) under the following parameters: 300kV and 975
µF capacity; 1 µg of plasmid DNA/ 106 cells. Efficiency of transfection was >95%.

FLOW CYTOMETRY AND PROTEIN STUDIES
Cells handled in different experimental settings were analyzed by flow cytometry
upon Annexin V-PE (BD Pharmingen)/ 7-aminoactinomycin D (7-AAD; Sigma) staining,
PI staining (Sigma) or BrdU incorporation (FITC BrdU Flow kit, BD Pharmingen).
FACS analysis was performed on a BD FACSCanto instrument (Becton Dickinson)
measuring 30,000 events for each sample.
Western blot analyses were performed as described (Chen et al., 2007).
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1 x 107 cells were cultured in hypoxia for 48 hours. Cells were then washed and
cross-linked for 10 min at a room temperature using 1% formaldehyde in PBS. The
reaction was stopped, by adding 0.25 M glycine in PBS. The cells were harvested and the
DNA was sheared by sonication in lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl,
1% NP-40) supplemented with 1% SDS, using a Branson SONIFIER 250 (Wolf
Laboratories Lmd, UK) to generate DNA fragments $600 bp. Cell lysates were diluted
ten times with lysis buffer to reduce the SDS final concentration to 0.1%. Lysates were
precleared with protein A/G agarose beads (Pierce, Rockford, IL) for 4 hr at 4°C, and
were then incubated overnight at 4°C with the respective primary antibodies. Immune
complexes were collected on Protein A/G agarose beads overnight at 4°C. Samples were
dialyzed twice against dialysis buffer (2 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0).
Following 4 washes in 1 ml wash buffer (100 mM Tris-HCl pH 8.0, 500 mM LiCl, 1%
NP-40); immune complexes were eluted from the beads by vigorously shaking twice for
15 minutes in 150 µl of 50mM NaHCO3, 1% SDS. Cross-linking was reversed by
incubation in 0.15 M NaCl overnight at 65°C. Each sample’s DNA was ethanol
precipitated and purified using QIAprep spin miniprep kit (Qiagen). DNA was
resuspended in 100 µl of TE buffer. Finally, each sample was PCR amplified using
appropriate oligonucleotides as primers (Table 7), and the results were visualized on 2%
agarose gels.
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NOTCH-1

EXPRESSION LEVELS ARE ELEVATED IN BOTH MESOTHELIOMA CELL LINES AND

SPECIMENS AS COMPARED TO THEIR NORMAL COUNTERPARTS

First, we measured the expression levels of Notch receptors, ligands and
downstream Notch targets in 8 ME compared to 3 HM. Western blot analyses showed
that all ME had increased Notch-1, Jagged-1 (and, to a lesser extent, Notch-3) expression
levels as compared to HM (Fig. 13A). According to the pattern of expression of Notch
receptors and ligands, ME displayed increased expression of the Notch downstream
targets HES-1, HEY-1 and HES-5 as compared to HM (Fig. 13B, Top). Treatment of ME
with the proteasome inhibitor MG132 led to an increase of the Notch-1IC expression,
suggesting activation followed by degradation (Gupta-Rossi et al., 2001) in these cells as
compared to HM (Fig. 13B, bottom). ME appeared to have significantly decreased (or
abolished) Notch-2 expression levels as compared to HM (Fig. 13A). Notably, we
detected Notch-2 immunoreactivity only in one frozen MM out of 25 specimens
analyzed, while the same samples tested positive for Notch-1IC staining, indicating that in
MM samples Notch-2 protein is poorly or not expressed (Graziani et al., 2008). These
results were confirmed at the mRNA level. ME and MM cells had substantially higher
levels of Notch1 mRNA as compared to HP, while the opposite was measured with
Notch2 mRNA (Fig. 13C). Based on HEY1 and HES5 (Fig. 13D) results, Notch signaling
is elevated (> 10-fold) in ME and MM compared to HP, and Notch-1 appears to play a
predominant role in this activation. The mRNA expression pattern in ME mimics what
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was observed in MM, suggesting that our in vitro cell line is a good model for studying
MM.

Figure 13. Expression of Notch signaling components in primary human mesothelial
cell cultures (HM), mesothelioma cell lines (ME), microdissected lung pleura (HP)
and microdissected mesothelioma cells (MM). (A) Western blot analysis performed on
3 independent HM and 8 ME of the indicated gene products. Note upregulated Notch-1
receptor and Jagged-1 ligand in ME compared to HM. Notch-3 also appears to be
upregulated in ME compared to HM. (B) Top; Western blot analysis of the Notch
downstream target HES-1, HEY-1 and HES-5 in HM and ME. Bottom; Western blot
analysis of Notch-1IC in HM2b and ME17 in the presence (+) and in the absence (-) of the
proteasome inhibitor MG132 (10 µM final concentration). Cell extracts were prepared 24
hr after MG132 addition. (C) Real time PCR analysis performed on RNA extracted from
HM (a colums), HP (b columns), ME (c colums) and MM (d colums). Expression of the
indicated mRNAs was normalized for 18S rRNA expression of each sample. Columns in
the histograms represent the averages of results obtained in 4 independent experiments (4
microdissected, frozen lungs, 4 microdissected, frozen MM, 4 HM and 4 ME). Error bars
represent standard deviation. T test P values: * (ME vs. HM), > 0.0001; ** (MM vs. HP),
0.0004; # (ME vs. HM), 0.0001; ## (MM vs. HM), > 0.0001. (D) Real Time PCR
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analysis performed on RNA extracted from HM, HP, ME and MM. Expression of the
indicated mRNAs was performed and normalized as described in C. T test P values: ‘
(ME vs. HM), > 0.0001; “ (MM vs. HP), 0.0012; ^ (ME vs. HM); > 0.0001; ^^ (MM vs.
HP), 0.0004. Courtesy of Irene Graziani.

INHIBITION OF NOTCH-1 CAUSES ME CELL DEATH, BOTH IN NORMOXIA AND HYPOXIA.
To understand the role of Notch-1 expression in ME and MM, we artificially
inhibited Notch-1 in ME, and analyzed the biological effects of such manipulation. We
employed a specific shRNA targeting Notch1 (shNotch-1) expressed using tetracyclineinducible lentiviral system activated by doxycycline treatment. Abrogation of Notch-1
signaling using this approach caused complete ME cell death both in normoxia (Fig.
14A) and under hypoxia (not shown). Similar effect on cell viability was observed after
GSI treatment, the effects however appeared to be greater under hypoxia. This is
reflected by a 6.72 ± 0.58 fold increase of Annexin V/ 7’AAD staining of various ME
treated with GSI (5µM) cultured under hypoxia (Fig. 14B) compared to a 3.22 ± 0.49 (P
value > 0.01) fold increase in cell death observed in normoxia. Both artificial downregulation of Notch-1 and GSI treatment appeared to depress the Akt-1 pathway activity.
Artificial down-regulation of Notch-1 using a small interfering RNA (siRNA) targeting
Notch1 under hypoxia caused decreased phosphorylation of PDK-1, Akt-1 and the
downstream effector mTOR protein expression (Fig. 14C). Downregulation of Notch-1
through siRNA caused increased expression of Notch-2 and decreased expression of
Notch-3 and -4. This indicated that Notch-1 may negatively regulate Notch-2, while
positively regulating Notch-3 and -4 expression in ME.
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Figure 14. Down-regulation of Notch-1 in ME leads to cell death both in normoxia
and hypoxia. (A) representative down-regulation of Notch-1 expression obtained using a
lentiviral vector that expresses a short hairpin targeting the Notch-1 mRNA (shNotch-1)
upon stimulation with doxycycline. Top; Western blot analysis of Notch-1 in shNotch-1
and control cells (pDest) 24 and 48 hr after doxycycline addition. Middle; Cristal violet
staining of either shNotch-1 and control cell cultures 5 days after doxycycline treatment.
Bottom; quantification of 4 independent experiments (10,000 alive cells were plated in
each 100 mm dish before doxycycline stimulation). Error bars represent standard
deviation. P value: * >0.0001. These experiments were performed in a standard incubator
(21% oxygen, 5% CO2). (B) representative Annexin V/7 Aminoactinomycin D (7AAD)
staining of a ME treated either with DMSO (Top) or with 5 µM GSI in DMSO (Bottom).
All cells were cultured under hypoxia. (C) Western blot analysis of the indicated gene
products of ME14 treated either with a control siRNA (Control) or with a siRNA
targeting the Notch-1 mRNA (siNotch-1). The analysis was performed 48 hr after
transfection. All cells were cultured in hypoxia. (D) Western blot analysis of the
indicated gene products of ME16 treated with the specified concentrations of the GSI.
Analysis was performed 24 hr after GSI treatment. All cells were cultured in hypoxia.
Experiments were replicated three times.
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Treatment of ME cells with GSI caused a dose-dependent accumulation of the

transmembrane (uncleaved) form of Notch-1, accompanied by a progressive decrease of
Notch-1IC and HEY-1 expression (all effects indicative of an effective Notch-1 inhibition;
Fig. 14D). Alongside Notch-1 inhibition Akt-1 was progressively losing phosphorylation
on Ser-473, which suggested decreasing activity of this kinase (Fig. 14D). Accumulation
of transmembrane (uncleaved) form of the receptor after GSI treatment was most
pronounced for Notch-1 isoform as compared to the other Notch paralogs (Fig. 14D),
indicating that Notch-1 was the major isoform of the receptor stabilized by the GSI in
ME.
Since we found that inhibition of Notch-1 using different strategies causes
decreased signaling through Akt-1 pathway, we wanted to determine whether expression
of active form of Akt-1, can result in a decrease of GSI induced cell death. ME
transfection with constitutively active form of Akt-1 (myrAkt) substantially rescued GSIinduced cell death by ~50% (Fig. 15A). This rescue was paralleled by the reactivation of
Akt-1 signaling as indicated by increased p-mTOR expression in myrAkt-transfected
cells (Fig. 15B). Similar results were found after downregulation of Notch-1 in ME cells
using siRNA. ME cells transfected with siRNA targeting the Notch1 mRNA displayed
decreased Notch-1 protein expression (Fig. 15C, lanes b and d) and reduced viability
under hypoxia (Fig. 15D, column b). When co-transfected with myr-Akt, ME cells still
have decreased Notch-1 expression levels, but their viability was restored (Fig. 15D,
column d).
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Figure 15. Active Akt-1 rescues apoptosis caused by Notch-1 inhibition (A) Annexin
V/7 aminoacinomycin D (7AAD) staining of the cells treated as in B. Each subpanel has
been assigned with a letter, which correspond to each lane shown in B. (B) Western blot
analysis of the indicated gene products performed on ME15 cells transfected with a
control plasmid (pUSE) or with a plasmid expressing myristoylated (active) Akt-1
(myrAkt). Transfected cells were either treated with DMSO or with 2 µM GSI in DMSO.
24 hr after treatment cells were assayed for apoptosis A. (C) ME14 transfected with
pUSE (control, lanes a and b) or with myrAkt (lanes c and d) and cotransfected with
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either a control siRNA (C, lanes a and c) or with a siRNA targeting the Notch1 mRNA
(siN1, lanes b and d). Western blot analysis of the indicated proteins. (D) Crystal Violet
staining of colonies obtained 5 days after cotransfecting ME11, 12, 13 and 14 with the
nucleic acids specified in C. After transfection, 10,000 live cells (as for trypan blue
staining) for each sample were seeded in T75 flasks. Colonies were stained and counted 5
days after seeding. The bars are the average of 4 independent experiments (one for each
cell line). Error bars represent standard deviation. Bars: a, pUSE + control siRNA
cotransfection; b, pUSE + siNotch-1 cotransfection; c, myrAkt + control siRNA
cotransfection; d, myrAkt + siNotch-1 cotransfection. P values: * (a vs. b) > 0.0001; **
(d vs. b) 0.003. ME11, 12, 13 and 14 cell lines were derived from different patients. (E)
Two representative microscopical fields of the samples reported in panel D, column a.
Original magnification 40X. (F) Western blot analysis of ME cells transfected with either
a control siRNA or with a siRNA to Notch1.
These observations further confirmed that Notch-1 provides survival signals to
ME under hypoxia mainly through the Akt-1 signaling pathway, and that a depressed
level of Akt-1 activation contributes to ME cell death upon Notch-1 down-regulation,
obtained either through genetic manipulation or chemical inhibition.

NOTCH-2 SIGNALING CONTRASTS THE NOTCH-1 PRO-SURVIVAL SIGNALS IN ME CELLS.
In contrast to the elevated levels of Notch-1 in ME and MM, we observed reduced
(or suppressed) Notch-2 expression in both ME and MM samples as compared to their
normal counterparts (Fig. 13). Our results confirm that Notch-2 signaling induced
programmed cell death in ME, and this effect was largely mediated through modulation
of Akt-1 activity, since Notch-2IC expression depressed Akt-1 signaling, and the
introduction of a constitutively active Akt-1 mutant reversed the pro-apoptotic effects
induced by Notch-2IC under hypoxia (Graziani et al., 2008).
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NOTCH-1 AND NOTCH-2 HAVE OPPOSITE EFFECTS ON THE AKT-1 SIGNALING PATHWAY
BECAUSE OF THEIR OPPOSITE REGULATION OF PTEN.
In response to various growth factors and adhesion molecules PI3 kinase is
activated, which in turn phosphorylates PIP2 to generate PIP3. PIP3 acts as a second
messenger to recruit PDK-1 kinase to the plasma membrane, and this stimulates PDK-1dependent phosphorylation of Akt-1 (reviewed in Cantley, 2002). PIP3 is the major
substrate of multifunctional phosphatase PTEN; therefore PTEN acts as a major tumor
suppressor gene by reducing the cellular amounts of a second messenger that induces
Akt-1 activation, which in turn promotes cell survival and proliferation (Cantley, 2002).
A recent study showed that loss of PTEN leads to resistance of Notch inhibition in some
T-ALL cells (Palomero et al., 2007), suggesting, for the first time, a link between Notch1 oncogenicity and PTEN activity. We investigated the possibility that activation of
either Notch-1 or Notch-2 can have opposite effects on Akt -1 phosphorylation due to the
opposite regulation of the PTEN gene. This was analyzed both at the protein and at the
mRNA level. We over-expressed Notch-1IC in ME using a doxycycline-inducible
lentiviral vector. When we induced Notch-1IC we observed a 3.1-fold reduction in PTEN
protein levels (Fig. 16A, compare lanes b and d).
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Figure 16. Notch-1 and Notch-2 have opposite effects on PTEN expression both at
the protein and at the mRNA level. (A) Western blot analysis of the indicated gene
products of ME14 transduced with either a control lentivirus (pDest) or with a lentiviral
vector that expressed Notch-1IC upon doxycycline treatment (Notch-1), lanes a-d, or ME
transfected with either a control siRNA (Control) or a siRNA targeting the Notch-1
mRNA, lanes e and f. (B) Western blot analysis of the indicated gene products of ME14
transduced with either a control lentivirus (pDest) or with a lentiviral vector that
expressed Notch-2IC upon doxycycline treatment (Notch-2). Note clone specific effects of
doxycycline exposure on PTEN expression (compare A to B). (C) Real time PCR
analysis of the PTEN mRNA measured in ME14 transfected with a control plasmid
(black column) or with a plasmid expressing Notch-1IC (gray column). The error bars
represent standard deviation of 4 independent experiments (ME14, 15, 16 and 17). (D)
Real time PCR analysis of the PTEN mRNA measured in ME cells transfected with a
control plasmid (black column) or with a plasmid expressing Notch-2IC (gray column).
The error bars represent standard deviation of 4 independent experiments (ME14, 15, 16
and 17). PTEN mRNA levels were normalized for 18S rRNA expression in each
experiment. P values: * > 0.01; ** > 0.0001. All experiments were performed in hypoxia.
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Doxycycline appeared to non-specifically up-regulate PTEN in these cells, but this
effect was mostly suppressed by Notch-1IC over-expression. We measured the PTEN
mRNA levels in ME transiently transfected with a plasmid expressing Notch-1IC cells and
we observed a 2.4-fold reduction of the PTEN mRNA (Fig. 16C). When we decreased
Notch-1 expression using a siRNA targeting Notch-1 in the same cells, we observed a 4.4
fold increase of PTEN protein expression (Fig. 16A, compare lanes e and f). Opposite
effects were observed when we expressed Notch-2IC in the same ME cells. Doxycyclineinduced expression of Notch-2IC caused a 4.2-fold increase in PTEN expression (Fig.
16B), paralleled by a 3.2-fold increase of the PTEN mRNA levels (Fig. 16D).
Combined, the data suggested that the opposite effects on Akt-1 activation
mediated by Notch-1 and Notch-2 signaling in ME, and differential effects on ME cell
survival, could have resulted from an opposite regulation of those two Notch isoforms on
the PTEN promoter. To ascertain whether such Notch regulation was direct, we assayed
the PTEN promoter region by ChIP assay. More specifically, we probed the 2646 bp long
region between positions -3033 and -387 of the PTEN promoter (+1 is the PTEN
initiation codon) using 11 partially overlapping amplicons derived by the use of 11 oligo
pairs (Table 6).
A 215 bp DNA fragment of the PTEN promoter (positions -602 to -387) was coimmmunoprecipitated alongside Notch-1 in ME14 cultured under hypoxia in three
independent experiments (Fig. 17). The fragment of the PTEN promoter that Notch-1 was
found to interact with contains a CBF-1 consensus sequence, suggesting direct regulation
of the PTEN promoter by Notch-1 in ME cells.
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Table 6. A list of oligonucleotides used for ChIP experiment on the PTEN
promoter:
PF1
PF2
PF3
PF4
PF5
PF6
PF7
PF8
PF9
PR1
PR2
PR3
PR4
PR5
PR6
PR7
PR8
PR9
PC1F
PC1R
PC2F
PC2R
H1F
H1R

5’-GTCACTTGGCTGAGTCCACA-3’
5’-TCGGCTGAGAGCTTTCATTT-3’
5’-GTAGTTCTACTTCCTAAGGG-3’
5’-TTCCCCAACTAGGGACACAC-3’
5’-AGGTCGATGTAGAGCAAGGA-3’
5’-TGAGAACCGAGCTTGACTCC-3’
5’-GCAAAAGGAAAGAGCGAATG-3’
5’-ATGTGGCGGGACTCTTTATG-3’
5’-GCCGAGGCTTAGCTCGTTAT-3’
5’-GCAAGCCAAAGGACTGAGAC-3’
5’-CATTCGCTCTTTCCTTTTGC-3’
5’-GTTGCAACAAACGTCCAGTC-3’
5’-GGAGTCAAGCTCGGTTCTCA-3’
5’-GGAACTACTTTCCGAAGGAG-3’
5’-CAGCGTGTATCACCTCATCC-3’
5’-GAGGCGAGGATAACGAGCTA-3’
5’-GAGGCTGCACGGTTAGAAAA-3’
5’-CATAAAGAGTCCCGCCACAT-3’
5’-TGGGTTTCTGGGCAGAGG-3’
5’-GGTAGGAGGGGGCAGAGC-3’
5’-TTCTCCTGAAAGGGAAGGTG-3’
5’-GGAGGCAGTAGAAGGGGAGAG-3’
5’-AGCGTGGGAAAGGATGGTTG-3’
5’-CTCGCTTCATGCTGGCTCCC-3’
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Figure 17. Notch-1 directly interacts with the PTEN promoter within a region
between position -602 and -387 (+1 is the PTEN start codon). ME14 cells were
cultured in three 150 mm dishes, incubated in hypoxia for 48 hr, and fixed in 1%
formaldehyde. Crosslinking was blocked with 250 mM glycine, cells were rinsed with
PBS and lysed. Cell lysates were combined, DNA was fragmented using a sonicator to
yield DNA fragments smaller than 600 bp and immunoprecipitated with antibodies and
controls. After washing Protein A- conjugated sephacryl beads, the DNA-protein
complexes were eluted from the beads, the crosslinking was reversed overnight at 65° C,
and DNA was purified using Qiagen columns. Of the 50 µl of the total volume, 2 µl were
used for PCR reactions (45 cycles). The reactions shown here were obtained using the
primers PC1F and PC1R (Table 6). No positive amplification was obtained using any
other couple of primers specified in Table 6, with the exception of the input DNAs in
three separate experiments. Lanes: M, molecular weight marker; H, H2O as template, 7;
Rabbit polyclonal antibody anti human IL7 (negative control); G, rabbit pre immune
serum (negative control); N1, rabbit polyclonal antibody anti human Notch-1 (C20, Santa
Cruz Biotechnologies); IN, 1/100 of the input DNA. We used as positive control a 167 bp
amplicon corresponding to bases -157 to +10 of the HEY1 promoter (+1 is the HEY1
initiation codon) amplified with primers H1F and H1R (Table 6) in each ChIP
experiment (not shown).
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In this chapter we show that MM cell survival requires Notch-1 expression and
signaling. Notch-1 mediates its effects by affecting the Akt-1 signaling pathway through
regulation of PTEN expression. These results confirm what was observed in T-ALL cells
(Palomero et al., 2007), and strongly suggest that the crosstalk between Notch-1 and Akt1 pathways may be of general validity in cancer and may have far-reaching therapeutic
implications.
In contrast to Notch-1, Notch-2 plays a tumor suppressive role in MM, by
depressing the PIP3/PTEN/Akt-1 axis. Such opposing roles of Notch-1 and Notch-2 in
cancers are not unprecedented, as it is known that the different Notch receptors display
diversity in their functions (Shimizu et al., 2002). In breast cancer there is strong
evidence that Notch-1 and -4 are oncogenic, while Notch-2 may play a tumor suppressive
role (O’Neil et al., 2007). Biologically, there is evidence that Notch-2 has an opposite
effect compared to Notch-1 and Notch-4 in breast cancer MDA-MB231 cells (O’Neil et
al., 2007). Examples of opposite effects of Notch-2 and Notch-1 have been discovered in
multiple myeloma (Nefedova et al., 2004) and embryonal brain tumors (Fan et al. 2004).
Biochemically, there is a body of published evidence that the transcriptional activity of
Notch-2 is dramatically lower than that of Notch-1 or Notch-3 (Shimizu et al., 2002).
Moreover, expression of Notch-2 together with either Notch-1 or Notch-3 inhibits their
transcriptional activity (Shimizu et al. 2002). The molecular mechanism(s) for these
differential effects is not known. It should be pointed out that the postulated transactivation domain (TAD) is the least conserved region between Notch paralogs (Kurooka
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et al., 1998). It has been proposed that all four Notch paralogs bind to CBF-1 (Nam et
al., 2007). It is possible that either Notch-2 is not as effective as Notch-1 or Notch-3 in
stabilizing the interaction between MAML1 and CBF-1 or in recruiting coactivators such
as p300 to the Notch transcriptional complex. Alternatively, it is possible that Notch-2
does not displace co-repressors such as SMRT from CSL. The molecular composition of
the Notch transcriptional complex including Notch-1 or Notch-2 at the PTEN promoter
will have to be determined in future studies.
It is reasonable to suggest that the cell environment will also contribute to the role
each Notch receptor plays in any given tumor, and that in certain contexts Notch-1 and
Notch-2 can have opposite biological effects. The mechanism of these differing effects is
still unclear. It is not clear whether Notch-2 acts by antagonizing Notch-1 (for example,
by competing for co-activators and CBF-1) or the two paralogs have independent or
opposing effects on certain downstream targets.
Since Notch signaling does not rely on amplification phosphorylation cascades
(such as the ERK signaling pathway), the strength and duration of Notch stimulation can
play a critical role. We have shown, as have others, that microenvironmental condition,
such as hypoxia, can also alter the biological significance of Notch signaling (Gustafsson
et al., 2005, Chen et al., 2007). For these reasons we have tested our cell systems using
different levels of expression, different duration of Notch activation and different oxygen
concentrations. Although quantitatively variable, our results invariably led to the same
qualitative conclusions (e.g., Notch-1 plays a pro-oncogenic role in MM, while Notch-2
appears to be oncosuppressive in this malignancy).
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ChIP assays suggested that Notch-1 could directly regulate PTEN promoter in

ME. The fragment we co-immunoprecipitated includes the CBF-1 consensus sequence
(cGtGGGAA), previously shown to be bound by CBF-1 in gel mobility assays in vitro
(Nam et al., 2007). Using luciferase assays and RT-PCR analysis, Whelan et al. (2007)
showed Notch-1 direct regulation of the PTEN promoter mediated by CBF-1 binding in
the same region where we immunoprecipitated Notch-1 in ChIP assays, thus supporting
our data. On the other hand, in T-ALL cells Notch-1 appears to regulate this promoter
indirectly through HES-1 (Palomero et al., 2007). It is possible that these apparent
differences may be tissue-specific.
Notch-1 inhibition using GSI appeared to induce apoptosis of ME most efficiently
in hypoxic conditions (Fig. 14B). This may have profound therapeutic implications
because MM is highly hypoxic (Klabatsa et al., 2006). The availability of a drug that
specifically targets these malignant cells in hypoxia may prove to be ideal for future
therapeutic regimens, and may lead to a more rational design of combination therapies.

CHAPTER 5
THE ROLE OF NOTCH SIGNALING IN ADENOCARCINOMA OF THE LUNG

ABSTRACT
A hypoxic tumor microenvironment supports cancer stem cell survival (Keith and
Simon, 2007) and causes poor response to standard chemotherapy and tumor recurrence
(Milas and Hittelman, 2009). Inhibition of Notch-1 signaling, obtained through genetic
manipulation or !-secretase inhibitor (GSI) treatment in adenocarcinoma of the lung
(ACL) cells causes apoptosis specifically under hypoxia. Akt-1 activation is a key
downstream mediator of Notch-1 pro-survival effects under hypoxic conditions.
Expression of constitutively active Akt-1 in ACL cells under hypoxia rescued most of the
toxic effects caused by Notch inhibition. Notch-1 regulates Akt-1 activation through two
major mechanisms: repression of phosphatase and tensin homolog (PTEN) expression
and induction of the insulin-like growth factor receptor-1 (IGF-1R). The latter regulation
seems to be the major determinant of Akt-1 activation in ACL cells, since Notch-1
signaling deeply affects Akt-1 activation in PTEN-/- ACL cells. Both the downregulation
of Insulin Receptor Substrate 1 (IRS-1) and dominant-negative IGF-1R sensitized ACL
cells GSI-induced apoptosis. Conversely, overexpression of IGF-1R under the control of
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a CMV promoter protected ACL cells from the toxic effects of Notch-1 inhibition.
Inhibition of Notch-1 (obtained either through genetic manipulation or GSI treatment)
caused reduced IGF-1R expression, both at the protein and at the mRNA level, while
forced Notch-1 expression caused opposite effects in a panel of cancer cell lines. ChIP
experiments suggested Notch-1 direct regulation of the IGF-1R promoter. Experiments in
which human ACL cells were injected in mice confirmed elevated and specific coexpression of Notch-1IC, IGF-1R and pAkt-1 in hypoxic tumor areas.
Our data provide a mechanistic explanation for Notch-1 mediated pro-survival
function in hypoxic ACL tumor microenvironment. The results identify additional
molecular targets that may synergize with Notch-1 inhibition for ACL treatment.

INTRODUCTION
Notch signaling is an evolutionarily conserved pathway responsible for critical
cell fate decisions during development and post-natal life (Artavanis-Tsakonas et al.,
1999). Notch receptors (Notch-1 through -4) and ligands have been linked to cancer,
although the exact role that each isoform plays seems to be tissue- and context-dependent
(Miele et al., 2006). Alteration of expression levels of Notch signaling pathway
components or their mutations can contribute to tumorigenesis in both positive and
negative ways. In some organs Notch can serve as dominant oncogene; in others it can
act as a tumor suppressor gene, insofar as the outcome of Notch signaling is strictly
context, time and dosage dependent (Maillard and Pear, 2003). Notch’s role in non-small
cell lung cancer (NSCLC) still awaits a better understanding. A pro-oncogenic role for
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Notch-3 has been proposed for a subset of NSCLCs (Dang et al., 2000, Haruki et al.,
2005, Konishi et al., 2007). We showed that targeting Notch-1, either using short hairpin
RNA (shRNA) or a GSI, caused ACL cells to undergo apoptosis specifically under
hypoxia (Chen et al., 2007), a condition typical for ACL in vivo (Chen and Dehdashti,
2005). Re-expression of intracellular (active) Notch-1 (Notch-1IC) rescued the proapoptotic effects of GSI (Chen et al., 2007). In this chapter we unveiled the mechanisms
responsible for Notch-1-dependent pro-survival signals to ACL cells under hypoxia.
Notch-1 activation in 1% oxygen appears to be hypoxia inducible factor 1& (HIF-1&)
dependent, because HIF1! siRNA reduced Notch-1IC expression and the Notch
downstream target Hes-1 (Fig. 18), confirming previous results (Gustafsson et al., 2005).

Figure 18. Notch-1 activation in ACL cells under hypoxia is HIF-1& dependent. (a)
Representative Western blot analysis of A549 cells transfected with either a control
siRNA (cont) or with a siRNA targeting the HIF1! mRNA (siHIF-1&). (b) Quantitative
RT-PCR of the Hes1 mRNA in A549 transfected with either a control siRNA (cont, black
column) or with a siRNA targeting the HIF1! mRNA (siHIF-1&, gray column). mRNA
levels were normalized for 18S rRNA expression levels. Columns represent the average
of three independent experiments. Error bars represent SD.
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Unless otherwise specified, all experiments were performed in 1% O2, 5% CO2,
94% N2 (hypoxia). Cells grown in hypoxia were maintained in chambers (Stem Cell
Technologies) filled with a certified mixture of aforementioned gases (Airgas North
Central) at 37 °C. MiniOX1 oxygen meters (Mine Safety Appliances Company) were
used to measure oxygen concentration. The experiments shown here were performed on
ACL lines A549, H1299 and H1755 (ATCC). Some experiments were performed in ACL
cell line H1650 (Fig. 24), while other cell lines are specified in Fig. 28. All cell lines
were fingerprinted using the GenePrint fluorescent STR system (Promega).

OLIGONUCLEOTIDES, ANTIBODIES, PLASMIDS, RETROVIRAL VECTORS AND SIRNAS
IGF1R-CBF1-Up-F

TGTGTGTGTCCTGGATTTGG

IGF1R-CBF1-Up-R

AGAAACGCGGAGTCAAAATG

IGF1R-CBF1-DWN-F

GGTTGCCGAGGGTATGCA

IGF1R-CBF1-DWN-R

GTGAAGGCTCAGTCGTGATTTTT

IGF1R-CBF1-DWN-probe 6FAM-TGCCGATTAACTTTG-MGBNFQ
b-globin-F

CCAGCCTTATCCCAACCATA

b-globin-R

TATCATGCCTCTTTGCACCA

Table 7. A list of oligonucleotides used for ChIP experiment on the
IGF-1R promoter
A list of all oligonucleotides used in this chapter is reported in Table 8. A list of
all antibodies used in this chapter is reported in Table 9.

!

Gene

Primer Sequence

%-globin-F

5’-CCAGCCTTATCCCAACCATA-3’

%-globin-R

5’- TATCATGCCTCTTTGCACCA-3’

BCL2A1 F

5’-TCTCAGCACATTGCCTCAAC-3’

BCL2A1 R

5’-AGTCCTGAGCCAGCCTGTAA-3’

Bcl2A1-F-BamH1

5’-GGGGGATCCAATGACAGACTGTGAATTTGG-3’

Bcl2A1-R- XhoI

5’-GGGCTCGAGTCAACAGTATTGCTTCAGGAG-3’

Casp-1 F

5’-GCTTTCTGCTCTTCCACACC-3’

Casp-1 R

5’-CATCTGGCTGCTCAAATGAA-3

Notch-1 F

5’-TGTTGTGTGTCATGCCAGTG-3’

Notch-1 R

5’-AACATCTTGGGACGCATCTG-3’

Hes1 F

5’-TCAACACGACACCGGATAAA-3’

Hes1 R

5’-CCGCGAGCTATCTTTCTTCA-3’

HeyL-F-XhoI

5’-GGGCTCGAGATGAAGCGACCCAAGGAGC-3’

HEYL-R-BamHI

5’-GGGGGATCCTCAGAAAGCCCCGATTTCAGTG-3’

IGF-1R F

5’-AACCCCAAGACTGAGGTGTG-3’

IGF-1R R

5’-TGACATCTCTCCGCTTCCTT-3’

IGF1R-CBF1-Up-F

5’-TGTGTGTGTCCTGGATTTGG-3’

IGF1R-CBF1-Up-R

5’-AGAAACGCGGAGTCAAAATG-3’

IGF1R-CBF1-DWN-F

5’-GGTTGCCGAGGGTATGCA-3’

IGF1R-CBF1-DWN-R

5’-GTGAAGGCTCAGTCGTGATTTTT-3’

IGF1R-CBF1-DWN-probe

5’-6FAM-TGCCGATTAACTTTG-MGBNFQ-3’

PTEN F

5’-ACCAGGACCAGAGGAAACCT-3’

PTEN R

5’-GCTAGCCTCTGGATTTGACG-3’

18S F

5’-TGATTAAGTCCCTGCCCTTTGT-3’

18S R

5’-TCAAGTTCGACCGTCTTCTCAG-3’

Human GAPDH F

5’- AGGCCCCGGGATGCTAGTG-3’

Human GAPDH R

5’- CACACGCGACTCCACCCATC-3’

Mouse GAPDH F

5’-AGCACAACTCAAAACTACCTGCA-3’

Mouse GAPDH R

5’- TGAGGTGTTTTGCTCCCAGT-3’

Table 8. A list of all oligonucleotides used in Chapter 5
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Target

Type

Company

Cat. number

Notch-1 IC (Val1744)

Rabbit polyclonal

Cell Signaling

2421

Acetyl Histone H3

Rabbit polyclonal

Millipore

06-599B

Akt-1 (G-5)

Mouse monoclonal

Santa Cruz Biotech.

55523

Bcl2A1

Rabbit polyclonal

Abcam

45413

Bcl-xL (54H6)

Rabbit monoclonal

Cell Signaling

2764

Caspase-1 (A-19)

Rabbit polyclonal

Santa Cruz Biotech.

622

GAPDH

Mouse monoclonal

Chemicon

MAB374

GFP

Rabbit polyclonal

Abcam

Ab290

Glut-1

Rabbit polyclonal

Abcam

Ab15309

HIF1& (H-206)

Rabbit polyclonal

Santa Cruz Biotech.

10790

HIF1& (H1alpha67)

Mouse monoclonal

Abcam

Ab1

IGF1R% (C-20)

Rabbit polyclonal

Santa Cruz Biotech.

713

IgG

Rabbit polyclonal

Santa Cruz Biotech.

2027

IgG

Rabbit polyclonal

Millipore

PP64B

IgG

Mouse polyclonal

AbCam

18448

IRS-1 (H-165)

Rabbit polyclonal

Santa Cruz Biotech.

7200

MAML1

Rabbit polyclonal

Millipore

AB5975

Mcl-1 (S-19)

Rabbit polyclonal

Santa Cruz Biotech.

819
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mTOR (H-226)

Rabbit polyclonal

Santa Cruz Biotech.

8319

NF-"B p50 (E-50)

Mouse monoclonal

Santa Cruz Biotech.

8414

Notch-1 (C-20)

Rabbit polyclonal

Santa Cruz Biotech.

6014

P300 (H-272)

Rabbit polyclonal

Santa Cruz Biotech.

8981

PDK-1

Rabbit polyclonal

Cell Signaling

3062

PTEN

Rabbit polyclonal

Cell Signaling

9552

PTEN (A2B1)

Mouse monoclonal

Santa Cruz Biotech.

7974

p-Akt (Ser473)

Rabbit monoclonal

Cell Signaling

4058

p-Akt (Ser473) (D9E)

Rabbit monoclonal

Cell Signaling

4060

p-IGF-1R (Tyr980)

Rabbit monoclonal

Cell Signaling

4568

p-mTOR (Ser2448)

Rabbit polyclonal

Cell Signaling

2971

p-PDK-1 (Ser241)

Rabbit polyclonal

Cell Signaling

3061

AlexaFluor 568

Rabbit IgG labeling kit

Zenon

Z25306

AlexaFluor 488

Rabbit IgG labeling kit

Zenon

Z25302

AlexaFluor 488

mouse IgG labeling kit

Zenon

Z25002

Table 9. A list of all antibodies used in Chapter 5

The plasmid encoding constitutively active Akt-1 (myr-Akt1) was from Upstate
Biotechnology. The plasmid encoding full-length IGF-1R was previously described
(Bocchetta et al., 2008), the plasmid encoding dominant-negative IGF-1R was a gift from
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Dr Hua Zhang (University of Minnesota), the plasmid encoding dominant-negative
MAML1 was previously described (Weng et al., 2003). The plasmids encoding Hes1 was
from Invitrogen. The plasmid encoding Hes5 was from OriGene. The plasmid encoding
c-myc was from AddGene. The plasmid encoding HeyL was obtained by amplifying the
HeyL cDNA from a liver cDNA library. This cDNA was subsequently cloned in the Xho
I/Bam HI sites of pcDNA3 (Invitrogen). The Bcl2A1 expressing plasmid was constructed
following a similar strategy: the complete CDS was PCR amplified from a lung cDNA
library and cloned into the Bam HI/ Xho I sites of pcDNA4 (Invitrogen). The
development of stably transduced, tetracycline-inducible ACL cells expressing Notch-1IC
within the pLenti4/TO/V5-DEST (Invitrogen) backbone has been previously described
(Chen et al., 2007). siRNA to Notch1 and IRS1 were from Santa Cruz Biotechnology;
siRNA to HIF1! was from Qiagen, while siRNA negative control was the Allstars
negative control (Qiagen). Transient transfections were done using an electroporator
(GenePulserII, Bio-Rad) under the following parameters: 300 kV, 975 µF; 1 µg of
plasmid DNA/106 cells or 20 pmol siRNA/106 cells. Efficiency of transfection was >95%.

MICE AND MOUSE PROCEDURES
6 weeks old female NOD.CB17-Prkdcscid/J mice (Jackson Laboratories) were
injected in the tail vein with 5 x 106 cells (A549, H1299, H1755 in separate experiments)
in 100 µl of sterile saline solution. Mice were housed in a pathogen-free animal facility at
Loyola University Medical Center. All procedures were done in accordance with the
Institutional Animal Care and Use Committee of the Loyola University Chicago Medical
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Center. Animals were monitored until they reached the endpoint (dyspnea). At the time
of euthanasia, human cells comprised 93±0.8% of the total lungs of mice. Tumor burden
quantification was performed using quantitative PCR measuring human versus mouse
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. After sequence alignments
of the human and mouse GAPDH genomic regions (Clustalw software), we designed
primers discriminating the two genes (Table 8). Primers were carefully validated, and
calibration curves to match Real Time PCR results to cell number were developed. DNA
was extracted from the whole left lung, the whole left liver lobe, and the whole left
cerebral hemisphere of each mouse (Fig. 32 and Table 8). Organs were excised and flash
frozen. 8µm-thick slides were used for standard immunofluorescence experiments.

CELL VIABILITY STUDIES AND GENE AND PROTEIN EXPRESSION ANALYSIS
Annexin V/7-aminoactinomycin D (7-AAD) staining (cell viability) assays,
quantitative

RT-PCR

(using

SYBR

green

incorporation),

Western

blot

and

immunohistochemistry assays were performed as described in Chapter 4. Pathway
specific arrays based on quantitative RT-PCR were from SuperArray. Results were
confirmed in targeted quantitative-RT-PCR experiments. The GSI MRK-003 was
dissolved in DMSO to 40 mM final concentration. The working concentrations and the
duration of exposure used in each experiment are specified in figure legends.
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End-point or Q-PCR based ChIP assays were performed as described in Chapter 4
with

a

few

modifications.

CT

values

obtained

in

association

with

each

immunoprecipitation reaction were normalized for "globin. The average value of three
pre-immune IgG was arbitrarily set to 1, and the "globin normalized values of each
immunoprecipitation reaction were expressed as fold enrichment over the values obtained
for the pre-immune IgGs.

STATISTICAL ANALYSES.
Statistical analyses were performed using Student’s t-test. Values were considered
statistically significant at P < 0.05 in two-tailed tests.

RESULTS

NOTCH NEGATIVELY REGULATES PTEN EXPRESSION IN ACL
In other systems, including MM, Notch-1 positively regulates Akt-1 activation by
suppressing PTEN transcription (Chapter 4, Palomero et al., 2007). We asked whether
Notch-1 influences PTEN expression in ACL cells. After manipulation of Notch-1
expression in those cells, both PTEN protein and mRNA expression levels were
determined (Fig. 19). Artificial downregulation of Notch-1 using specific siRNA caused
a ~3-fold increase in the PTEN expression, while overexpression of Notch-1IC led to a
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~5-fold reduction in PTEN expression levels (Fig. 19a). On the contrary, both genetic
and chemical inhibition of Notch-1 caused an increase in PTEN mRNA expression (Fig.
19b).

Figure 19. Notch-1 negatively regulates PTEN expression in ACL cells. (a) Western
blot analysis of the indicated proteins in H1299 cells transfected with a control siRNA
(cont, left), with a siRNA targeting the Notch1 mRNA (siN1), with a control plasmid
(cont, right) or with a plasmid expressing Notch-1IC (N1). Bands in Western blot
experiments were quantitatively evaluated using a FujiFilm LAS-3000 imaging system.
(b) H1299 cells were transfected with either a control siRNA (cont, left) or with a siRNA
targeting the Notch1 mRNA (siN1). Alternatively, H1299 cells were treated with either
DMSO (cont, right) or with 20 µM GSI for 48 hr. The mRNA levels were measured
using quantitative RT-PCR and normalized for 18S rRNA content. Bars represent
average of three independent experiments. Error bars represent SD. We obtained similar
results in A549 and H1755 cells (one experiment for each cell line).
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In parallel, to assess whether Notch-1 can stimulate signaling through Akt-1
pathway affecting other components, we looked at the upstream activator of Akt-1
namely phosphoinositide-dependent kinase-1 (PDK-1; Alessi et al. 1997) and
downstream effector mammalian target of rapamycin (mTOR; Fig. 32a-c; Ruggero and
Pandolfi, 2003). Forced expression of Notch-1IC using doxycycline inducible system
caused increased phosphorylation of PDK-1, Akt-1 and mTOR (Fig. 20a, compare lanes
2 and 4). Notch-1 stimulation of Akt activation is elicited in a dose-dependent fashion
(Fig. 20b). Inhibition of Notch-1 expression using siRNA resulted in reduced signaling
through Akt-1 pathway, as judged by a reduced phosporylation of Akt-1, PDK-1 and
mTOR proteins (Fig. 20c).

Figure 20. Notch-1 regulates Akt-1 phosphorylation in ACL cells under hypoxia. (a)
A549 cells were transduced with an empty lentiviral vector (A549-TR-D) or with a
lentivirus in which Notch-1IC was under the control of a doxycycline-inducible promoter
(A549-TR-N1). Upon doxycycline induction of Notch-1IC, increased phosphorylation of
Akt-1, PDK-1 and mTOR was observed (compare lanes 2 and 4). (b) A549-TR-N1 cells
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were treated with the indicated concentrations of doxycycline. Notch-1 appeared to
stimulate Akt-1 phosphorylation in a dose-dependent fashion. (c) Notch-1 artificial
downregulation obtained using a siRNA to Notch-1 caused decreased activation of PDK1, Akt-1 and mTOR. A549 cells were transfected with either a commercial control
siRNA (cont) or a siRNA targeting the Notch-1 mRNA (siN1). Cells were assayed 48 hr
after transfection using Western blot.

Fig. 21. Akt-1 activation protects ACL cells from apoptosis triggered by Notch
inhibition under hypoxia. Left: Western blot analysis of the indicated proteins in A549
cells transfected with either a control vector (cont) or with a vector expressing an NH2terminal myristoylatable Akt-1 (constitutively active Akt, or aAkt; Chapter 4). Right:
Annexin V/7-AAD staining of A549 cells transfected with either a control plasmid (cont)
or with aAkt, and exposed to 20 µM GSI for 48 hr. The histogram represents the average
of three independent experiments. Error bars represent SD. Black columns: alive cells;
gray columns: dead cells (annexin V positive).
Activated Akt-1 plays a major role in Notch-mediated protection from apoptosis under
hypoxia, since transient transfection of ACL cells with an NH2-terminal myristoylable
Akt-1 (constitutively active Akt-1, or aAkt) rescued 71.59 ± 2.18% cells from GSIinduced apoptosis (Fig. 21). Importantly hypoxia alone causes more than 6% A549 cell
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death, suggesting that aAkt can rescue GSI induced cell death almost to the basal level.
High concentrations of GSI caused nearly complete cell death 48 hr after exposure. Even
under these conditions, aAkt kept alive about 50% of transfected cells (Fig. 22).

Figure 22. Constitutively active Akt-1 rescues ACL cells from cell death even at very
high GSI concentrations (100 µM) under hypoxia. Representative experiment. Top:
two ACL lines transfected with either a control plasmid (pUSE) or with a plasmid
expressing constitutively active Akt-1 (aAkt). Western blot analysis of the indicated cell
lines. Bottom: annexin V/7-AAD staining of A549 cells transfected with the indicated
plasmids and treated with either vehicle alone (DMSO) or 100 µM GSI. It should be
noted that the percentage of GSI induced cell death is dependent on GSI concentration
but also on cell confluency (more confluent cells were more resistant to GSI treatment).
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In this study we used a GSI concentration of 20 µM and a cell confluency of 70-80%
in most experiments. Under these conditions hypoxia induces 23±3% cell death in 48
hours.
Percentage of GSI induced cell death depended not only on GSI concentration, but also
on cell confluency. Taken together, these observations suggest that Akt-1 activation
could be the major target of Notch-1 induced ACL cells’ resistance to apoptosis under
hypoxia.

NOTCH-1 REGULATES

THE

EXPRESSION

OF CASPASE-1 AND

BCL2-A1 INDIRECTLY

THROUGH AKT-1
Through its regulation of Akt-1, Notch-1 indirectly regulated the expression of
Bcl2-A1 and caspase-1, two proteins that are involved in apoptosis response (Fig. 23).
Notch-1 inhibition (obtained through shRNA to Notch1 or GSI treatment) resulted in the
reduced Bcl2-A1 and increased caspase-1 expression. When considered independently,
those two molecules can rescue only a fraction of GSI-induced ACL cell death under
hypoxia. Inhibition of caspase-1 (obtained by exposing ACL cells to the caspase-1
inhibitor Y-VAD) did not significantly rescue GSI induced cell death under hypoxia,
while transient transfection of A549 cells with a plasmid expressing Bcl2-A1 marginally
rescued GSI-induced apoptosis under hypoxia (Fig. 23b). Transfection of ACL cells with
constitutively active Akt-1 produces the opposite effects of Notch-1 inhibition on the
mRNA expression levels of caspase1 and Bcl2A1 (Fig. 23c). Furthermore, Bcl2-A1 and
caspase-1 expression appeared to be regulated by Akt-1 activity, a downstream target of
Notch-1. From these results we concluded that Notch-1 inhibition (GSI- or shRNA-
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mediated) led to increased caspase-1 (a pro-apoptotic protein; Bhanoori et al., 2003)
and decreased Bcl2-A1 expression (an anti-apoptotic protein; Beverly and Varmus, 2009).

Figure 23. Notch-1 inhibition leads to reduced Bcl2-A1 and increased caspase-1
expression. (a) Left: quantitative RT-PCR performed on A549 cells transduced with a
control shRNA lentiviral vector (black colums) or with a lentiviral vector expressing an
shRNA targeting the Notch1 mRNA (gray columns). Results were normalized for 18S
rRNA content in each sample. Right: Western blot analysis of A549 cells treated either
vehicle alone (DMSO) or GSI (MRK-003) for 48 hr under hypoxia. Note increased
expression of caspase-1, while Bcl2-A1 expression levels appear to be undetectable after
GSI treatment; these results mirror what was observed when targeting Notch1 genetically.
(b) Annexin V/7-AAD staining of A549 cells exposed to 20 µM GSI for 48 hr in hypoxia
and: vehicle alone (DMSO); 92 µM Ac-YVAD-CMK (Alexis Biochemicals; Y-VAD);
transfected with pcDNA3 (cont) or with a plasmid overexpressing Bcl2A1. Black colums,
alive cells; gray columns, Annexin V positive cells. (c) Quantitative RT-PCR of the
indicated mRNAs in A549 cells transfected with either a control vector (pUSE) or with a
vector expressing aAkt. All histogram columns in this figure represent averages of 3
independent experiments. Error bars represent standard deviation. *: P<0.01; **: P<0.05.
None of these two proteins (taken individually) appeared to play a major role in the proapoptotic effects of Notch-1 inhibition in ACL cells under hypoxia. Bcl2-A1 and
caspase-1 appeared rather to be downstream effectors of Akt-1. Since we determined that
Akt-1 is a major target of Notch-1 signaling in ACL cells under hypoxia, we inferred that
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both caspase-1 and Bcl2-A1 are indirectly regulated by Notch-1 through Akt-1. It is
likely that those two proteins participate in the anti-apoptotic effects of Notch-1 signaling
in ACL cells under hypoxia, although none of them seemed to have a predominant effect
in this phenomenon when studied individually.

HYPOXIA/NOTCH-1 REGULATES IGF-1R EXPRESSION
To test whether Notch-1 regulation of Akt-1 activation was mainly a result of
Notch-1 control of PTEN expression, we modulated the expression of Notch-1 in PTEN-/ACL cell line H1650 (Guo et al., 2008). Even in cells lacking the expression of PTEN,
manipulation of Notch-1 expression levels still resulted in altered expression levels of the
Akt-1 pathway components. Downregulation of endogenous Notch-1 using siRNA led to
decreased phosphorylation of PDK-1, Akt-1 and mTOR, while forced expression of
Notch-1IC led to the opposite effects (Fig. 24). These results suggest that factors other
than PTEN were responsible for Notch-1-mediated Akt-1 activation in ACL cells under
hypoxia.
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Figure 24. Notch-1 modulates the activation levels of PDK-1, Akt-1 and mTOR in
PTEN null ACL cells. Western blot analysis of the indicated proteins. Antibodies
against phosphorylated forms of the indicated proteins are labeled p. H1650 cells were
transfected with either a control siRNA (cont), with a siRNA targeting the Notch1 mRNA
(siN1), with a control plasmid (pcDNA) or with a plasmid expressing Notch1IC (N1IC).
Cells were analyzed 48 hr after transfection.
In several models activation of the IGF-1R and its adaptor protein IRS-1 induce
the majority of Akt-1 signaling (Adams et al., 2000). We hypothesized a possible
crosstalk between Notch-1 and IGF-1 signaling because IGF-1 autocrine signaling can
regulate HIF-1& expression (Treins et al., 2005). Furthermore, hypoxia increases the
expression of an IGF-1 and IGF-1R (Moromisato et al., 1996; Fig. 25a). Culturing cells
under low oxygen condition causes increase in IGF-1R protein expression (Fig. 25a, top),
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as well as 3.5 fold in the expression of IGF1R mRNA (Fig. 25a, bottom). Both
transient siRNA to IRS1 and dominant-negative IGF-1R sensitized ACL cells to GSI
treatment (Fig. 25b-c), reinforcing the possible link between IGF-1R and Notch-1
signaling. On the other hand, expression of IGF-1R under the regulation of a CMV
promoter protected ACL cells from GSI-induced apoptosis (not shown).

Figure 25. Hypoxia/Notch-1 regulates IGF-1R expression; manipulation of IGF-1R
signaling modulates the rate of GSI induced cell death under hypoxia. (a) A549 cells
cultured in a standard incubator or under hypoxia. Top: representative Western blot
analysis of the indicated proteins; bottom, quantitative RT-PCR of the IGF-1R mRNA in
A549 grown either in normoxia (21% O2, black column) or under hypoxia (1% O2, gray
columns). Messenger RNA levels were normalized for 18S rRNA content. Columns
represent the average of three independent experiments. Error bars represent SD. (b)
siRNA to IRS1 sensitizes ACL cells to GSI induced cell death under hypoxia. A549 cells
were transfected with either a control siRNA (cont) or with a siRNA targeting the IRS1
mRNA. Top: representative Western blot analysis of the indicated proteins; bottom:
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Annexin V/7AAD staining of cells transfected with siRNA and exposed to 20 µM GSI
under hypoxia for 48 hr. Black column, alive cells; gray column, Annexin V positive
cells. Columns represent the average of three independent experiments. Error bars
representing SD. P value is indicated. (c) Dominant negative IGF-1R sensitizes ACL
cells to GSI induced cell death under hypoxia. A549 cells were transfected with either a
control plasmid (cont) or with a plasmid expressing a dominant-negative IGF-1R. Top,
representative Western blot analysis of the indicated proteins; bottom, Annexin V/7AAD
staining of cells transfected with plasmids and exposed to 20 µM GSI under hypoxia for
48 hr. Black column, alive cells; gray column, Annexin V positive cells. Columns
represent the average of three independent experiments. Error bars represent SD. P value
is indicated. (d) Notch-1 regulates the expression of the IGF-1R both at the protein and at
the mRNA levels. Top: representative Western blot of the indicated proteins in A549
cells trasfected with a control plasmid (cont, left) or with a plasmid expressing Notch-1IC
(N1IC), or transfected with a control siRNA (cont, right) or with a siRNA targeting the
Notch1 mRNA (siN1). Bottom: quantitative RT-PCR of the IGF1R mRNA in A549
transfected with the nucleic acids described above. Additionally, A549 were exposed to
DMSO (c) or with 20 µM GSI (GSI) for 48 hr under hypoxia. mRNA values were
normalized for 18S rRNA expression levels. *: P< 0.001; **: P< 0.001; ***: P< 0.01.
Columns represent the average of three independent experiments. Error bars represent
SD. All experiments shown in Figure 25 were confirmed in H1299 and H1755 cells (one
experiment for each cell line).
We then asked if Notch-1 could regulate the expression of IGF-1R. We
determined that siRNA to Notch1 reduced the expression of IGF-1R protein and mRNA
(Fig. 25d). Similar effect on IGF-1R expression was observed when cells were treated
with GSI (Fig. 26a). Those results were reproduced in two other cell lines (Fig. 26a),
suggesting a more general role of this phenomenon. In other ACL cell lines tested,
expression of IGF-1R increased when Notch-1IC was overexpressed, while the IGF-1R
expression level was reduced by GSI treatment. To determine whether the effects on IGF1R expression are mediated specifically by Notch-1 isoform, we forced the expression of
Notch-1IC, and found increased IGF-1R protein and mRNA levels (Fig. 25d, Fig. 26a).
Furthermore, the GSI-induced repression of IGF-1R expression was reversed after
induction of Notch-1IC (Fig. 26b). Doxycycline treatment alone reduced the IGF-1R
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expression levels in control cells, suggesting that it can nonspecifically affect IGF-1R
expression. However, induction of Notch-1IC (obtained through doxycycline treatment)
led to a ~5-fold increase in the IGF-1R expression levels (Fig. 26 b, compare lanes 3 and
4). Notch-1IC failed to restore the IGF-1R expression levels completely, possibly because
of the compounding doxycycline effects (compare lanes 1 and 2).

Figure 26. Notch-1 regulates IGF-1R expression. (a) Western blot analysis of the
indicated proteins. H1755 and H1299 cells were either transfected with a control plasmid
(N1IC -) or with a plasmid expressing Notch-1IC (N1IC +). Additionally, A549 cells were
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treated with either DMSO (GSI -) or 20 µM GSI for 48hr (GSI +). All experiments
were performed in hypoxia. The two panels for IGF-1R represent two different exposure
times of the same gel. (b) A549-TR-DEST (lanes 1 and 2) and A549-TR-N1 (lanes 3 and
4) were exposed to either 1 µg/ml doxycycline (DOX), 20 µM GSI or both for 48 hr. All
experiments were performed under hypoxia.
Collectively, this data suggest Notch-1 regulation of IGF-1R expression under
hypoxia. To explain the contribution of HIF-1& to this observation we down-regulated
HIF1! using siRNA. ACL cells with downregulated HIF-1& showed reduced IGF-1R
expression (Fig. 27), further confirming the cooperation between HIF-1& and Notch-1
signaling under hypoxia (Chen et al., 2007; Gustafsson et al., 2005).

Fig. 27. Artificial down-regulation of HIF-1& causes reduced expression of the IGF1R in ACL cells under hypoxia. A549 cells were transfected with either a control
siRNA or with a siRNA targeting the HIF1! mRNA. 48 hr after transfection cells were
assayed by Western blot analysis for the indicated proteins.
Notch-1 regulation of IGF-1R expression was not restricted to ACL cells, since
siRNA to Notch-1 depressed the IGF-1R expression in cell lines of different tissue
derivation (Fig. 28). Down-regulation of Notch-1 caused (to different extents in different
cell lines) reduction of the IGF-1R expression levels. Notably, in 293FT cells (human
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embryonic kidney cell line stably expressing SV40), we observed the opposite effect
(down-regulation of Notch-1 caused increased expression of the IGF-1R). This result
(which still suggests Notch-1 regulation of the IGF-1R promoter) is not surprising,
because Notch-1 has been described to occasionally cause opposite effects in different
tissues due to context-dependent reasons.

Figure 28. Notch-1 regulates IGF-1R expression in cell lines obtained from different
tissues. HeLa (cervical cancer), MCF7 (breast cancer), ME16 (malignant mesothelioma)
CaSki (cervical cancer) cells were transfected with either a control siRNA or with a
siRNA targeting the Notch1 mRNA. 48 hr after transfection cells were assayed by
Western blot analysis for the specified proteins. Experiments were performed under
hypoxia.
NOTCH-1 DIRECTLY REGULATES IGF1R TRANSCRIPTION
To investigate the mechanisms through which Notch-1 regulates IGF-1R
expression we transfected ACL cells with known Notch downstream targets (namely,
Hes-1, Hes-5, Hey-1, Hey-L and c-Myc (Klinakis et al., 2006; Palomero et al., 2006)).
None of these proteins significantly affected IGF-1R expression levels, neither at the
protein nor at the mRNA level (not shown). We then hypothesized a Notch-1 direct
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regulation of the IGF1R promoter. There are two canonical CBF-1 consensus
sequences in the DNA region surrounding the IGF1R initiation codon (position +1): one
at position -612 and a second at position +1478 (Fig. 29).

Figure 29. Region of the IGF1R that we analyzed by ChIP for the indicated proteins.
We focused our attention on two DNA fragments containing canonical CBF-1 binding
sites. Gray: region upstream of the initiation of transcription; darker pink: 5’ UTR; lighter
pink: first fragment of the CDS (+1, initiation of translation); green: 5’ region of the first
intron. (a) At the +1478 region we detected association of Notch-1, MAML-1 and p300.
Upon transfection with dominant negative MAML-1 (DN-MAML-GFP) (b) these
proteins are no longer associated with this DNA region, and the amount of acetylated
histone H3 is significantly reduced (see Fig. 30).
Notably, we failed to detect association of HIF-1& to the +1478 site in two independent
ChIP experiments. This suggests that HIF-1& is not directly a part of the protein complex
present in this DNA region. Courtesy of Shuang Liang.
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We analyzed the association of Notch-1IC with these DNA regions using ChIP. We

found no association of Notch-1IC with the -612 site in 7 independent experiments.
Instead, Notch-1IC reproducibly associated with the +1478 site (Fig. 30, and Fig. 31a).

Figure 30. Notch-1 associates with the +1478 region of the IGF1R gene. End point
PCR-based ChIP experiment performed on A549 cells. We used two pre-immune IgG;
one from Millipore (IgG M) and one from Santa Cruz Biotechnology (IgG SC). Notch-1
was immunoprecipitated using the antibody C-20 (Santa Cruz Biotechnology). In this
experiment the +1478 region was amplified using primers different to those used in Fig.
31 (Table 7). 1/20 of input DNA was amplified using end point PCR. Experiment
performed by Sandra Eliasz and Shuang Liang.
We sought additional evidence that Notch-1IC stimulates transcription of the
IGF1R gene when associated with the +1478 region. To this end, we immunoprecipitated
Notch transcriptional coactivators including MAML-1 (Nam et al., 2006) and p300 (Fryer
et al., 2002); the +1478 DNA region coimmunoprecipitated with both proteins (Fig. 31a).
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Figure 31. Notch-1 associates with the +1478 region of the IGF1R gene alongside
MAML-1 and p300; transfection of ACL cells with dominant negative MAML-1
disrupts such assiociation. (a) Quantitative ChIP of the +1478 region (62 bp-long
TaqMan fragment) after immunoprecipitation of the indicated proteins in A549 cells
transfected with a control plasmid (black columns) or with a plasmid coding for dominant
negative MAML-1 (gray columns). The IgG column represents the average of three
different pre-immune IgG. Each column represents the average of four (black columns)
or five (gray columns) independent experiments (IgG bar represents 8 independent
immunoprecipitations). Error bars represent SD. (b) Representative Western blot analysis
of A549 cells transfected with either control plasmid or the plasmid expressing dominant
negative (dn) MAML-1 (visualized with an antibody against GFP). Note that upon
dnMAML-1 expression (24 hr after transfection), the expression levels of IGF-1R are
substantially decreased. All the experiments shown in this figure were conducted 24 hr
after transfection. This was because dnMAML-1 appeared to be toxic to ACL cells for
longer timepoints after transfection. Courtesy of Shuang Liang
.
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Transfection of ACL cells with a dominant-negative MAML-1 (dnMAML-1)

prevented the immunoprecipitation of the +1478 region with Notch-1IC, dnMAML-1 and
p300, and significantly decreased the amount of acetylated histone H3 at this site (Fig.
31a). This result can be explained by the requirement of a complete protein complex for
stable Notch-1 association with the +1478 region. Dominant negative MAML-1 lacks its
central domain responsible for p300 recruitment, which is replaced by green fluorescence
protein (GFP; Weng et al., 2003). Alternatively, the absence of p300 activity at this site
may decrease the overall acetylation of histone H3 (Fig. 31a) leading to a local
rearrangement of the chromatin structure that could render this region less accessible to
transcription factors/coactivators. Furthermore, transfection of ACL cells with dnMAML1 reduced the IGF-1R expression (Fig. 31b). Collectively, the above data suggest that
Notch-1 directly regulates IGF1R transcription through its association with the +1478
DNA region.

!

106!

IN VIVO MOLDEL OF ACL
We then asked if the HIF-1&/Notch-1/IGF-1R/Akt-1 circuitry would be active in
vivo in experimentally induced, human metastatic ACL in mice (Fig. 32).

Human/mouse cells

LUNG

LIVER

BRAIN

93 ± 0.8%

1.32 ± 0.082%

0.37 ± 0.22%

Figure 32. Metastatic ACL model in immunocompromized mice. Top: frontal and
side view of non-inflated lungs obtained from a mouse after euthanasia 18 weeks after
tail injection of 2.5x106 A549 cells. At this stage mice (which were previously monitored
daily and did not show signs of pain or distress) displayed mild dyspnea and irritability.
Since the whole lung appears to be mostly embodied in tumor masses, we decided to
include dyspnea associated to irritability (rapid movements, unwillingness of the mice to
be taken by the tail) as an additional endpoint for humanitarian reasons. However, the
size of the tumor was such that areas of hypoxia within the tumor masses were likely
present. The overall size of the tumors was the equivalent of a T1 (no larger than 3 cm)
stage according to the WHO/International Association for the Study of Lung Cancer
(http://my.iaslc.org/nav/index.pyt). Bottom: tumor burden quantification was performed
using quantitative PCR measuring human versus mouse glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene. After sequence alignments of the human and mouse
GAPDH genomic regions (Clustalw software), we designed primers discriminating the
two genes (Table 8). Primers were carefully validated, and calibration curves to match
Real Time PCR results to cell number were developed. The template total genomic DNA
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was represented by three independent aliquots of DNA extracted from the whole left
lung lobe, the whole left liver lobe, and the whole left cerebral hemisphere of each
mouse.
To this end, we performed a number of immunofluorescence experiments on snap
frozen, 8 µm thick tissue slides obtained from total of 6 mice. We used GLUT-1 as a
marker of hypoxia (Ebert et al., 1995; Behrooz and Ismail-Beigi, 1999) because it reliably
evidenced hypoxia in ACL cells, and because it was co-expressed with HIF-1& in tumor
samples (Fig. 33).

!
108!
Figure 33. GLUT-1 is an effective marker of hypoxia in ACL cells. (a-d)
immunofluorescence performed using an anti-GLUT-1 antibody on A549 cells cultured
in 21% oxygen (a and c) and in 1% oxygen (b and d). (a and b) pre-immune IgG
(negative control). Original magnification: 100X. (e) Western blot analysis of the
indicated proteins performed on H1299 cells cultured at the specified oxygen
concentrations. Courtesy of Shuang Liang.
GLUT-1 was co-expressed with HIF-1a in tumor samples (Fig. 34a). Strikingly,
only hypoxic tumor areas expressed Notch-1IC, maximally expressed IGF-1R, and
appeared to be the only tumor areas where Akt-1 phosphorylation was detectable (Fig.
34b-e). On the contrary, PTEN was never expressed in tumor areas that were
characterized by expression of hypoxic by marker GLUT-1 (Fig. 34f). IGF-1R appears to
be expressed also in non-hypoxic tumor areas. This suggests that Notch-1 is not the sole
regulator of IGF-1R expression. Upon stimulation, IGF-1R undergoes internalization,
degradation and recycling (Carelli et al., 1999; Romanelli et al., 2007). These phenomena
may artificially reduce the level of co-expression that we detected in our
immunofluorescence experiments. Furthermore, Akt-1 activation appears to be
maximally sustained in cells actively recycling IGF-1R (Romanelli et al., 2007).
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Figure 34. Notch-1IC is coexpressed in hypoxic tumor cells together with IGF-1R and
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phosphorylated Akt-1. Coimmunofluorescence stainings of the indicated proteins on
8 mm-thick slides obtained from tumor-bearing lungs of SCID mice injected with A549
cells through the tail vein. (a) coexpression of GLUT-1 and HIF-1a. (b) Co-expression of
GLUT-1 and Notch-1IC. (c) Expression of IGF-1R is maximal in GLUT-1 expressing
tumor cells. (d) Phosphorylated (S473) Akt-1 is detected in GLUT-1 expressing
(hypoxic) tumor cell only. (e) PTEN is expressed in GLUT-1 negative tumor cell only.
Note that GLUT-1 and PTEN positive cells appear to be contiguous. This is likely an
event due to the lateral, asymmetric nature of Notch signaling. In these experiments we
detected co-expression rather than co-localization because the different proteins assayed
here have different cellular localization (e.g., cell surface receptors, cytoplasmic proteins,
nuclear transcription factors). Bar, 20 mm. Courtesy of Shuang Liang.

DISCUSSION
In summary, results presented in Chapter 5 indicate that hypoxia (through HIF-1&) is
a major determinant of Notch-1 activation in vivo. This leads to strong Akt-1 activation
in part through PTEN repression but prevalently because Notch-1 regulates IGF-1R
expression (Fig. 35).
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Fig. 35. Schematic of Notch-1 regulation of Akt-1 activation under hypoxia in ACL

Our data suggest that in hypoxic tumor microenvironment HIF-1& potentiates the
transcriptional activities of Notch-1IC. This leads to two major events: suppression of
PTEN expression and, more importantly, upregulation of IGF-1R. Both events lead to
hyper-activation of Akt-1 in hypoxic tumor environment (Fig. 34). Our data have
potentially far-reaching implications for understanding the pathogenicity of ACL, and
can help to develop novel therapeutic strategies. Hypoxic tumor areas are likely to be
most resistant to apoptosis because of exacerbated Akt-1 activation, as a result of the
HIF-1&/Notch-1/IGF-1R circuitry. Our data suggest that chemotherapeutic intervention
that ultimately reduces the oxygen concentration within the tumor might s c x=v activate
Notch in hypoxic tumor tissue and promote the survival of tumor cells. This would
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explain recent data indicating that angiogenesis inhibitors, although reducing the size
of the primary tumors, appear to promote tumor invasiveness and metastasis (Paez-Ribes
et al., 2009; Ebos et al., 2009). This effect could be mediated by Notch-1 promotion of
metastases observed under hypoxia (Sahlgren et al., 2008). Markedly, hypoxia also
promotes the “stem-like” phenotype of putative tumor-initiating cells (Keith and Simon,
2007). In other models, such as breast, these cells are highly Notch signaling dependent
(Korkaya and Wicha, 2009). While such cells in NSCLC haven’t been definitively
identified, it stands to reason that if a slowly proliferating, highly drug-resistant cell
population exists within hypoxic tumor areas, the HIF-1&-Notch-IGF-1R-Akt-1 pathway
may be involved in their maintenance. Inhibiting Notch-1 through a GSI or other
pharmacological interventions in ACL may preferentially target hypoxic areas and the
tumor-initiating cells within them. For this reason, the use of Notch inhibitors in
combinations with inhibitors of the IGF-1/Akt-1 pathway and/or cytotoxic chemotherapy
may result in synergistic anti-tumor effects in ACL.

CHAPTER 6
GENERAL CONCLUSIONS

In my experiments throughout my PhD studies I have established that
there is a molecular circuitry that intimately involves insulin-like growth factor-1 (IGF-1)
and Notch-1 signaling interplay in two thoracic malignancies of different histological
derivation, namely malignant mesothelioma (MM) and non-small cell lung cancer
(NSCLC). In MM activation of the IGF-1/IGF-1R/Notch-1 axis seems to be required for
the maintenance of the malignant phenotype, irrespective of whether malignant
transformation is virally driven or caused by sporadic mutations. I have established that
in MM Notch-1 is an oncogene, while Notch-2 is a tumor suppressor. Accordingly,
Notch-1 expression and activation is always present in mesothelial malignant settings,
while Notch-2 expression is lost. Notch-1 activation appears to have effects on cell
proliferation and survival (the latter phenomenon in hypoxic conditions) mainly affecting
the PI3K/PDK-1/Akt-1 signaling axis. A similar situation takes place in NSCLC, where
Notch-1 provides critical pro-survival signals through the Akt-1 activation. In both
malignancies Notch-1 affects Akt-1 activation by depressing phosphatase and tensin
homolog (PTEN) transcription and by positively regulating insulin-like growth factor
receptor-1 (IGF-1R) expression (Fig. 34). To the best of my knowledge, this is the first
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time that Notch-1 has been implicated in the regulation of the IGF-1R. The PTEN
data confirm what was observed in T cell acute lymphoblastic leukemia (T-ALL;
Palomero et al., 2007). Since these mechanisms have been found in three different
malignancies (T-ALL, MM, and NSCLC), and they likely represent a universal way
through which Notch-1 promotes tumorigenicity. In some tissues, such as skin (Nickoloff
et al., 2002; Rangarajan et al., 2001), pulmonary neoroendocrine cells (Kunnimalaiyaan
and Chen, 2007), possibly medullary thyroid cells (Kunnimalaiyaan et al., 2007) Notch-1
acts as a tumor suppressor gene. It is possible that in these tissues Notch-1 regulates
PTEN and IGF-1R in opposite ways that those that I described. A hint that this could be
the case is provided by the results we obtained in 293 kidney cells: downregulation of
Notch-1 caused increased expression of the IGF-1R (e.g., the opposite of what is shown
in Fig. 25, 26, 28). The reason of these apparently contrasting regulations may be the
results of interactions with tissue specific transcription factors at the IGF-1R or PTEN
promoter. A good example in support of this interpretation is provided in breast cancer.
Estrogen depresses Notch-1 activity (Rizzo et al., 2008). However, in the absence of
estrogen, Notch-1IC interacts with estrogen receptors ER& alongside I"B kinase &
(IKK&) to promote estrogen receptor & (ER&)-specific transcription (Hao et al., 2009).
Finally, my data provide further explanations on why primary human mesothelial
cells are uniquely susceptible to SV40-mediated transformation (Bocchetta et al., 2000).
SV40 upregulates Notch-1 (Bocchetta et al., 2003) and IGF-1R (Porcu et al., 1992). My
data show that the SV40 Tag (together with cellular p53), also upregulates IGF-1, thus
exacerbating the IGF-1/IGF-1R autocrine loop.
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Altogether, my data and those provided by my colleagues in Dr Bocchetta’s

laboratory have provided a mechanistic explanation of Notch-1 mediated pro-oncogenic
activities and have identified novel targets for therapy of such deadly diseases such as
MM and NSCLC. In this process, I uncovered a novel viral mechanism to support
cellular transformation.
Future directions include: testing in the animal model whether GSI treatment can
actually specifically target hypoxic tumor tissue. Additionally, it would be important to
study whether Notch-1 is a master regulator of tumor cell metabolism. IGF-1 and insulin
signaling pathways are very ancient in the evolution of Metazoa (Pollak, 2008). During
evolution, insulin receptor (IR) and IGF-1R have diverged to regulate mainly
carbohydrate metabolism or cellular survival and proliferation, respectively. However,
these two receptors share very similar downstream signaling components. More
importantly, hybrid receptors comprised of IR and IGF-1R heterodimers are common in
cells expressing both receptors, including cancer cells (Adams et al., 2000). It will be
important to explore whether Notch-1 participates in the regulation of IR as well.
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